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Abstract: 
All organisms have a well-conserved heat shock response that is 
universal among species as diverse as bacteria, plants, and animals.  Upon 
heat stress, the heat shock transcription factor (HSF1) orchestrates the 
expression of molecular chaperones that allow the organism to cope with the 
cellular damage induced by the stress.  Interestingly, these molecular 
chaperones, or heat shock proteins, are amongst the most highly conserved 
proteins throughout bacteria, animal and plant kingdoms.  Because a high 
concentrations of damaged proteins is deleterious to cells, the heat shock 
response has become an integral survival response of living systems, one that 
rapidly evolving systems like cancer cells utilize quite efficiently.  Therefore, to 
further understand genetic instability disorders like cancer, and at the same 
time to broaden the identification of novel drug targets, we must first be 
capable of efficiently disrupting the chaperone-buffering system that maintains 
cancer cell survival.  
Recently, HSF1 has been found to promote cellular transformation in 
mammals.  My studies focus on the role of HSF1 in animal development and 
maintenance of the transformed phenotype using a highly-specific RNA 
 aptamer (iaRNAHSF) that binds to yeast, Drosophila, and mammalian HSF1.  In 
Drosophila, the expression of iaRNAHSF reduces normal expression of the 
Hsp83 chaperone and induces developmental abnormalities that mimic the 
spectrum of phenotypes previously reported when Hsp83 activity is reduced.  
Using Drosophila mutants as a model for tumorigenesis, I found that HSF1 
inhibition with iaRNAHSF effectively suppresses the abnormal growth 
phenotypes induced by constitutively active EGF receptor (EGFR) and Raf 
oncogene that normally function as part of the Hsp83-regulated cell survival 
pathway.  Moreover, HSF1 inhibition by this same iaRNAHSF in various human 
cancer lines resulted in the reduction of molecular chaperones that normally 
promote cell survival, thereby triggering apoptosis.  Collectively my studies 
demonstrate the potent application(s) of the RNA aptamer technology in 
investigating transcription regulation and cancer biology, as well as in testing 
of putative drug targets in vivo.  
 
 iii 
BIOGRAPHICAL SKETCH 
As a child, I grew up not knowing my real parents.  I remember my 
Grandmother, Maria Teresa, constantly reminding my older sister Krissia and 
me that someday my parents were going to come back and take us to the land 
of opportunities, “Los Estados Unidos”.  Not knowing my parents did not really 
bother me. On the contrary, I was glad that they were far away, because I 
knew that if they had stayed they would be buried in some dump somewhere 
in the highlands.   
During the late 1970!s, both of my parents were students in La 
Universidad Nacional de El Salvador, when the government shut down the 
universities and began to assassinate those professors and students that 
spoke against the injustices, which had been imposed by the fourteen families 
that controlled every aspect of the Salvadorean government and economy.  
Due to this event, my father was forced to quit on his third year of medical 
training.  One day, a soldier came up to my father and asked him if he could 
take a picture of him with his “beautiful” family: my mom, who had me inside 
her womb, and my older sister, who was only just over one year old.   Before 
my father could agree to this event, the soldier had already taken two pictures, 
one which was given to him, and the other picture which was property of the 
Salvadorean government, and ended up being posted in a bulletin board of 
suspected “outspoken” individuals, a mere assassination list.  After my mother 
had given birth to me, both of my parents decided to leave the country, simply 
because many of their friends had been taken into custody for “questioning” 
and never returned to their families.  In time, their body parts were found 
scattered throughout public places, including local Plazas.  Afraid for their 
lives, my parents began the three thousand mile journey toward North America 
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in hope a better life, leaving my sister and me under my grandmother!s care.  
In the years that followed, both of my parents worked in the strawberry, and 
broccoli fields of Southern California picking vegetables in order to send one 
hundred and fifty dollars a month to help my Grandmother for our care.   
Growing up in Chinameca, in the outskirts of El Salvador in the height of 
the war meant that school was almost always cancelled.  This did not stop my 
Grandmother, a retired school grade teacher, from attempting to give my sister 
and me a proper education.  During her career as a school teacher, she had 
practically taught everyone in our “pueblo” how to read and write, and for this 
reason, everyone treated her with great respect and admiration.  Without 
realizing it, I had joined the first grade already knowing how to read and write.  
During the nights, when the helicopters would fly over the hills dropping flares 
and bombs, my sister and I would read from old encyclopedias that my 
Grandmother had rescued from her school before it was burned to the ground 
during a battle.  At nights, when the “guerrillas/rebels” would try to ambush the 
government soldiers, we would go into our man made shelter and fall asleep to 
the sounds of troops running at a quick pace right in front of our house, 
helicopters flying low, nearby cries, bombs exploding followed by the rapid 
gunfire of a screaming M16 rifle, pppp…ppppp….pppppp….pppp….pppppp.   
Some nights the fighting would cease during the night, while other times, it 
would continue for days. 
One day, in the middle of the summer, my Grandmother came from the 
local telephone center excited.  As soon as she entered the house, she looked 
in my direction and said, “your parents are on their way, they!ll be here 
tomorrow!”  I did not know what to think, I felt happy that I was going to finally 
see my parents, at the same time I could not disguise my sadness, because I 
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knew that the day had finally arrived where I was going to leave everything I 
knew, everyone I loved, my family, my dog, my home.  My Grandmother, on 
the other hand seemed very happy, for it had been ten years since she had 
last seen her daughter.  On my twenty-first birthday, my Grandmother told me 
that on that day she felt very happy because she was finally going to spend a 
week with her daughter after almost a decade of being apart.  At the same 
time, she felt that every day during that week her heart was slowly being torn 
into pieces. 
During that week, my parents went to the American embassy in El 
Salvador to apply for my sister!s and my visa so that our family could be re-
united in the United States.  Even though both of my parents were permanent 
California residents, the embassy denied their request.  They said that in order 
for them to grant this petition, my parents would have to request our visas from 
the United States to the Salvadorean immigration agency.  And, since at the 
time El Salvador was still in civil war, visas were not easily granted, at least to 
those people who did not own property, or could not bribe the Salvadorean 
officials.  In turn, there would be another five to eight year wait period before 
the Salvadorean immigration agency would make their decision.  Both of my 
parents were greatly disappointed at this information.  They thanked the 
Ambassador for his advice and left the building.   
When my parents came from the American Embassy, I remember my 
mother saying, “like Hell I!m going to spend eight more years away from my 
children.”  The following day, just like our parents ten years prior, my sister 
and I began our three thousand mile journey to the United States in hope of a 
better life.  Within a month period, Krissia and I had illegally crossed three 
international borders and were enrolled in school using fake social security 
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numbers, both taking classes in a completely foreign language.  My mother 
said that if we were going to learn how to speak English, we had to “eat, sleep 
and dream in English”, speaking Spanish at the house was forbidden.  
Furthermore, we were enrolled in strictly English speaking courses.  In nine 
months, my sister and I were able to communicate with our peers, and within 
two years we were getting our first B!s and A!s  competing against native born 
English speakers.  It would be another ten years, after I was already attending 
my first year in college that I was finally granted “true” permanent resident 
status.  This was another battle, since I my university threatened to withdraw 
my enrollment because they couldn!t find a match for my proposed social 
security number, and because my “alien” number also did not match their 
records.  In other words, they were kicking me out of school even though I had 
a 3.75 GPA.  I decided to take my transcripts to the Salvadorean Embassy in 
Los Angeles and was determined not to leave the office until I pleaded my 
case to the Ambassador, I wanted to remain in school and get my bachelor!s 
degree.  That year, while the university denied me of financial aid, I worked in 
construction with my father in order to pay for my books and for my tuition.  
Fortunately, Ambassador Don Calderon Sol, granted me a one year visa, and 
a promise that he would personally oversee my “green card” application.  By 
the end of the year, I had a valid social security number and a valid spot in the 
university.  Within five years, I was the first of my family to graduate from 
college, obtaining two bachelors of science degrees, one in biochemistry and 
the other in microbiology.  While in college I successfully completed two 
research projects under two different advisors, one in each department, and 
also participated in a summer scientific research project in Palma de Mallorca, 
Spain.  During my final year at Cal Poly, I was selected as one of two students 
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to represent my university in the 2002 California State Undergraduate 
Research Competition.  That year, I applied to Cornell University and was 
admitted into the PhD program in biochemistry, cell and molecular biology 
(BMCB).  Since arriving at Cornell, I have completed all of my formal graduate 
courses in BMCB with a minor in genetics.  Besides science, my greatest 
passions include drinking good wines, listening music, making love, reading 
and studying Portuguese (not necessarily in that particular order).  Thinking 
back, my Grandmother was always right, my parents did return to El Salvador 
to bring my sister and me to “the land of opportunities, where dreams do come 
true”. 
 
 
 
 
 
 
 
 
Para mis hijos con todo corazón
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CHAPTER ONE:  INTRODUCTION 
 
 2 
All organisms have a well-conserved heat shock response that is 
universal among species as diverse as bacteria, plants and animals (Lindquist, 
and Craig, 1988a).  Upon heat stress, the heat shock transcription factor 
(HSF1) induces the expression of molecular chaperones that allows 
organisms cope with the protein damage caused by the stress.  Interestingly, 
these molecular chaperones, or heat shock proteins, are amongst the most 
highly conserved proteins throughout the animal and plant kingdoms 
(Hendrick, and Hartl, 1993; Lindquist, 1980).  Because a high concentration of 
heat-denatured proteins are deleterious to the cell, evolution puts strong 
selective pressure on living systems to elicit an efficient stress response, 
something that rapidly evolving systems like cancer cells utilize quite 
efficiently.  Therefore, to further understand genetic instability disorders like 
cancer, and at the same time to broaden the effort to identify novel proteins 
that promote cellular transformation, one must first be capable of efficiently 
disrupting the HSF1 mediated chaperone network that maintains cancer cell 
survival.   
 
1.1.  The Heat Shock Response 
The heat shock response is one of the most robust cellular responses 
to external stimuli found in nature.  Upon heat exposure, the general 
transcription and translation programs become rapidly attenuated.  At the 
same time, heat stress induces the robust transcription of heat shock genes, 
and the efficient translation of the heat shock gene mRNA transcripts.  In this 
way, living systems can quickly and efficiently synthesize heat shock proteins, 
or molecular chaperones that allow cells to overcome heat induced protein 
damage by catalyzing protein refolding reactions.  The rapid kinetics of cellular 
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reprogramming during heat exposure emphasizes the importance of 
maintaining the quality of cellular proteins necessary for survival.  Strikingly, 
there is a direct correlation between an organism!s environment and the 
temperature at which the heat shock response is triggered.  For instance, in 
Drosophila melanogaster heat shock is effectively triggered at temperatures 
that correlate to warm summer days, 33-37°C (Lindquist, 1980).  Among 
thermophilic bacteria actively growing at temperatures of 50°C, the heat shock 
response is triggered at approximately 60°C (Daniels, McKee, and Doolittle, 
1984).  In artic clams that live in temperatures near 0°C, the heat shock 
response is activated at around 5-10°C (Park, Ahn, and Lee, 2007). Among 
humans, the heat shock response is activated near fever level temperatures, 
~42°C.  These observations indicate that the heat shock response is regulated 
by intrinsic cellular factors (to be discussed later in this chapter), rather than by 
direct sensing of heat stress by HSF1 (Zhong, Orosz, and Wu, 1998).  To 
date, the most convincing in vivo evidence that supports this hypothesis 
derived from studies that introduced human HSF1 protein into Drosophila cells 
or Xenopus oocytes depleted of their endogenous HSF1 proteins.  In these 
experiments, the human HSF1 protein functionally complemented the loss of 
the endogenous HSF1, and remarkably, the human protein efficiently induced 
a robust heat shock response at the organisms! critical temperature (37°C for 
both Drosophila and Xenopus), instead of the human critical temperature of 
42°C (Clos, Rabindran, et al, 1993; Zuo, Rungger, and Voellmy, 1995).   
Lindquist and colleagues first proposed that heat shock proteins bind 
denatured proteins and catalyze protein-refolding reactions (Lindquist, 1980; 
DiDomenico, Bugaisky, and Lindquist, 1982; Pelham, 1986).  Indeed, induction 
of an effective heat shock response provides an advantageous biological 
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adaptive response to external stress that promotes cell survival by refolding 
heat denatured proteins.  In cases where the damage is too severe, heat 
shock proteins efficiently target heat denatured polypeptides for degradation 
(Freeman, and Morimoto, 1996).  By definition, chaperones constitute “a family 
of unrelated proteins that mediate the correct assembly of other polypeptides, 
but are not themselves components of the final functional structure” (Ellis, and 
van der Vies, 1991; Hendrick, and Hartl, 1993).  Intriguingly, upon exposure to 
elevated temperatures, chaperones become highly concentrated at the 
nucleus and the cytoskeleton, partly because these organelles experience the 
most protein damage (Welch, and Suhan, 1985; Lepock, Frey, et al, 2001).  If 
the stress is too severe and the cell can!t resume its normal transcriptional 
program or re-establish its normal cytoskeletal structure because of extensive 
protein damage, these organelles send specific signals to the mitochondria to 
initiate apoptosis.  Given the functional significance of these organelles in 
regulating almost every aspect of cellular homeostasis, and the strong 
selection pressures placed on living systems since the origins of life, it is not 
surprising that the heat shock response evolved to be highly sensitive to even 
slight changes in temperature.  
 
1.2  The HSF Family is Highly Conserved Among Eukaryotes 
HSF1 activates the expression of a specific set of heat shock genes, 
resulting in the accumulation of molecular chaperones that allow the organism 
to cope with cellular damage induced by the thermal stress.  Structural and 
biochemical studies reveal that the master regulator of heat shock gene 
expression, HSF1, is composed of at least three domains: a DNA binding 
domain (DBD), a trimerization domain (TD) and an acidic activation domain 
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(AD) (Figure 1.1)  (Green, Schuetz, et al, 1995; Peteranderl, and Nelson, 
1992; Pirkkala, Nykanen, and Sistonen, 2001; Sorger, and Nelson, 1989; 
Wisniewski, Orosz, et al, 1996; Wisniewski, Orosz, et al, 1996; Zuo, Rungger, 
and Voellmy, 1995).  Interestingly, the DBD is the most conserved HSF1 
domain across all members of the HSF family among different species (Figure 
1.2A) (For more detail on the conservation and structure of various HSF 
proteins among different eukaryotes see Pirkkala, Nykanen, and Sistonen, 
2001).  To date, the crystal and solution structures of Kluyveromyces lactis 
and D. melanogaster reveal that the HSF1 DBD is a typical helix-turn-helix 
domain comprised of three alpha helices, four beta strands, and a solvent 
exposed loop (Figure 1.2A & B) (Damberger, Pelton, et al, 1994; Harrison, 
Bohm, and Nelson, 1994; Littlefield, and Nelson, 1999; Vuister, Kim, et al, 
1994).  The HSF1 DBD third helix (H3) is the most conserved stretch of amino 
acids, consisting of mainly positively-charged residues that allow the molecule 
to make specific contacts with various phosphate groups on the major groove 
of heat shock gene promoters (Figure 1.2B) (Littlefield, and Nelson, 1999; 
Vuister, Kim, et al, 1994). 
The HSF1 preferred DNA binding sites are called the heat shock 
elements (HSE), and are composed of inverted repeats containing an nGAAn 
consensus sequence (Fernandes, Xiao, and Lis, 1994; Fernandes, Xiao, and 
Lis, 1995).  It has been observed that the relative affinity of HSF1 to different 
promoters is dependent on the specific arrangement and spacing of each HSE 
within promoters, and the proximity of HSF1 molecules to one another, since 
HSF1 binds to DNA in a cooperative manner (Amin, Fernandez, et al, 1994; 
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Figure 1.1:  Diagram of human heat shock transcription factor-1 (HSF1).  
In this depiction, HSF is composed of three main domains: DNA binding 
domain comprised of a typical helix-turn-helix, a homo-trimerization domain 
containing hydrophobic repeats (leucine zippers), and a transcriptional 
activation domain.  Amino acids labeled in black residues indicate serine 
phosphorylation sites that maintain HSF1 in a transcriptionally inactive state; 
while red-labeled residues indicate those sites that become modified to 
potentiate HSF1 trans-activation activity.  Repression of trimerization 
corresponds to sites that are bound to molecular chaperones that maintain 
HSF1 in a transcriptionally "inactive! monomer conformation (Modified from 
Voellmy R. 2004 Cell Stress & Chaperones). 
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Figure 1.2:  HSF1 has a !winged" helix-turn-helix motif that is highly 
conserved among eukaryotes.   
(A) Amino acid sequence alignment of the DNA binding domain between 
different eukaryotes: Arabidopsis thaliana (AtHSF), tomato (LeHSF8, LpHSF8, 
24,30), Kluyveromyces lactis (KlHSF), Saccharomyces cervisiae (ScHSF), 
Saccharomyces pombe (SpHSF), chicken (ChHSF), Mus muscus (MmHSF1, 
2), human (HuHSF1, 2) and Drosophila melanogaster (DmHSF) shows that 
the DBD is highly conserved, particularly in the DNA contact region, helix 3 
(H3) (Modified from Vuister G.W. et. al. 1994 Nature).  (B) The 1.75A crystal 
structure of Kluyveromyces lactis HSF-DBD complexed to DNA shows that the 
DBD is a typical "winged! helix-turn-helix structure.  In this illustration, helix-3 
recognizes and binds to the major groove of DNA that contains an NGAAN 
consensus sequence (Modified from Littlefield O and Nelson HC 1999 Nature). 
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Xiao, Perisic, and Lis, 1991).  In humans, it has been found that HSF1 and 
HSF2 have specific preferences for particular HSE arrangements on gene 
promoters: HSF1 prefers an array of 4-5 units of nGAAn pentameric 
consensus sequences, while HSF2 prefers 2-3 repeating units (Liu, Liu, et al, 
1997).  Therefore, it is likely that the observed developmental differences 
associated with HSF1-/- or HSF2-/- knock-out mice are due to differences in 
gene expression and the HSE composition of specific gene promoters that are 
regulated by each molecule (see section 1.6). 
The HSF1 trimerization domain consists of hydrophobic heptad repeats 
(HR-A/B & C) made of a series of helical coiled-coil domains known as "leucine 
zippers!.   In the absence of stress, HSF1 is maintained in a transcriptionally 
inactive state by associations with multi-chaperone complexes and the 
hydrophobic repeats (Figure 1.1) (Green, Schuetz, et al, 1995; Pirkkala, 
Nykanen, and Sistonen, 2001; Wisniewski, Orosz, et al, 1996; Rabindran, 
Haroun, et al, 1993; Zuo, Baler, et al, 1994).  At the same time, the 
hydrophobic repeats allow HSF1 to become a stable homotrimer after an initial 
heat shock exposure (Figure 1.1) (Sorger, and Nelson, 1989).  The HSF1 
acidic activation domain (AD) is located at the C-terminus and contains 
several acidic and hydrophobic residues that associate with the transcriptional 
apparatus to induce heat shock gene expression (Figure 1.1, CTR) 
(Wisniewski, Orosz, et al, 1996). Currently, strong evidence suggests that heat 
shock induces major conformational changes within the activation domain 
resulting in a dramatic increase in the AD helical content (Bulman, and Nelson, 
2005; Pattaramanon, Sangha, and Gafni, 2007).  It is hypothesized that these 
newly formed !-helices give the activation domain more rigidity, and allow 
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HSF1 to make specific contacts with proteins that modify the transcriptional 
machinery that results in elevated heat shock gene expression.  
 
1.3.  Heat Shock Transcription Factor Proteins 
In bacteria, the rpoH gene product (heat shock sigma factor-"32), is 
responsible for inducing the heat shock response.  Under regular growth 
conditions, "32 is maintained at low concentrations due to its rapid protein 
turnover; however during stress conditions, "32 concentrations increase rapidly 
by becoming part of the transcriptional apparatus that up-regulates its own 
expression levels as well as the expression of other heat shock genes 
(Grossman, Erickson, and Gross, 1984; Straus, Walter, and Gross, 1987).  
Among eukaryotes, the transcription factors that activate heat shock gene 
expression are called heat shock transcription factors (HSFs).  
Saccharomyces cerevisiae and Drosophila melanogaster express a single 
HSF1 protein that responds to a variety of other stress conditions including 
damage by reactive oxygen species and exposure to heavy metals 
(Wiederrecht, Seto, and Parker, 1988; Sorger, and Nelson, 1989; Clos, 
Westwood, et al, 1990).   
Plants and vertebrates have evolved multiple HSF isoforms that appear 
to have specialized functions  (Czarnecka-Verner, Yuan, et al, 2000; Nakai, 
and Morimoto, 1993; Nakai, Tanabe, et al, 1997; Rabindran, Giorgi, et al, 
1991; Sarge, Zimarino, et al, 1991; Schuetz, Gallo, et al, 1991; Xiao, Zuo, et 
al, 1999).  Strikingly, plants display the largest diversity of heat shock factors 
among all groups of organisms.  For example, Arabidopsis thaliana and 
Lycopersicum esculentum (tomato) express over 20 different HSF isoforms, 
each displaying distinct modes of regulation and activation (Czarnecka-Verner, 
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Yuan, et al, 2000; Czarnecka-Verner, Pan, et al, 2004; Nover, Bharti, et al, 
2001).  Vertebrates contain four HSF family members, three of which are 
found among mammals, HSF1, HSF2, and HSF4.  The fourth member, HSF3, 
is avian specific (Tanabe, Kawazoe, et al, 1998; Pirkkala, Nykanen, and 
Sistonen, 2001).   
In S. cerevisiae, HSF1 is essential for cellular viability and for 
vegetative growth (Wiederrecht, Seto, and Parker, 1988).  However, unlike 
yeast, animals do not require HSF1 activity for general cell growth; rather, 
HSF1 is required during specific developmental stages.  For instance, in 
Drosophila HSF1 activity is required only during early larval development and 
during oogenesis (Jedlicka, Mortin, and Wu, 1997), while in C. elegans HSF1 
is required for longevity (Morley, and Morimoto, 2004; Walker, Thompson, et 
al, 2003).  Among mammals, HSF1 is the transcription factor responsible for 
inducing the expression of molecular chaperones in response to a wide variety 
of stresses, including heat (Xiao, Zuo, et al, 1999; Sarge, Zimarino, et al, 
1991; Murray, Whitfield, et al, 2004).  Intriguingly, HSF1!s cytoprotective role 
during stress cannot be substituted by any other members of the HSF family 
(Xiao, Zuo, et al, 1999; McMillan, Christians, et al, 2002).   
Recently, HSF1 has been implicated as a “non-classical oncogene” 
because its activity promotes tumor formation and maintenance of the 
transformed phenotype in cancer cells, without affecting the viability of normal 
cells (Dai, Whitesell, et al, 2007).  Therefore, it seems that HSF1 functions to 
promote cell survival even under conditions that could potentially become 
deleterious to cells, such as development of the transformed state.   
Unlike HSF1, HSF2 does not regulate the expression of heat shock 
proteins (Kallio, Chang, et al, 2002; McMillan, Christians, et al, 2002; Wang, 
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Zhang, et al, 2003).  Instead, HSF2 is required specifically during mammalian 
embryogenesis and brain development (Kallio, Chang, et al, 2002; McMillan, 
Christians, et al, 2002; Paslaru, Morange, and Mezger, 2003).  The 
mammalian HSF4, although similar in structure to both HSF1 and HSF2, lacks 
an acidic activation domain (Pirkkala, Nykanen, and Sistonen, 2001).  
Interestingly, HSF4 is highly abundant within the eye tissues of mammals, and 
is apparently required for maintaining the integrity of the eye-lens and 
preventing cataract formation (Fujimoto, Izu, et al, 2004).  Because HSF4 does 
not contain an activation domain, it is currently believed that HSF4 is involved 
in attenuating heat shock gene expression by competing with HSF1 for binding 
to heat shock elements (Nakai, Tanabe, et al, 1997).  Amongst birds, HSF3 
has been found to work in concert with HSF1 to properly induce heat shock 
gene expression during heat stress (Nakai, and Morimoto, 1993; Tanabe, 
Kawazoe, et al, 1998). 
 
1.4.  HSF1 Controls Transcription of Heat Shock Genes at Multiple 
Levels 
The heat shock genes, as their name implies, were first identified in the 
1960!s in D. melanogaster by visualizing the decondensation of specific bands 
in the polytene chromosomes during temperature elevation {reviewed in 
(Ritossa, 1996)}.  The underlying mechanism for this "puffing! response is due 
to the decondensation of chromatin by the transcriptional apparatus at these 
highly induced loci (i.e, heat shock genes) (Jedlicka, Mortin, and Wu, 1997; 
Petesch, and Lis, 2008; Ritossa, 1996).  Over the last two decades, our group 
has focused in understanding the molecular mechanism of HSF1 mediated 
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gene expression using the Drosophila Hsp70 gene as a model (Lis, 1998; 
Saunders, Core, and Lis, 2006).   
Strikingly, immediately after cells are exposed to elevated 
temperatures, HSF1 becomes rapidly activated and transitions from an 
globular-monomeric form into a rigid-homotrimer form that binds heat shock 
gene promoters in a highly cooperative manner (Sorger, and Nelson, 1989; 
Westwood, and Wu, 1993; Xiao, Perisic, and Lis, 1991; Fernandes, Xiao, and 
Lis, 1994; Zuo, Baler, Dahl, and Voellmy, (1994); Fernandes, Xiao, and Lis, 
1995).  After the first few minutes following heat stress, HSF1 saturates the 
promoters of heat shock genes and remains at these sites throughout the 
duration of the heat shock response (Boehm, Saunders, et al, 2003).  Such 
HSF1 binding to heat shock promoters induces a highly orchestrated series of 
molecular events that results in over one hundred-fold gene expression (Lis, 
1998; Saunders, Core, and Lis, 2006).   
One major rate-limiting step that HSF1 must overcome in order to 
induce a robust heat shock response is the effective recognition of its cognate 
sites on DNA.  Under normal growth conditions, the GAGA Associated factor 
(GAF) is responsible for maintaining the Hsp70 promoter in a nucleosome-free 
"open! conformation that is feature is critical for effective HSF1 binding during 
heat stress (Figure 1.3A) (Shopland, Hirayoshi, et al, 1995; Tsukiyama, and 
Wu, 1995; Wilkins, and Lis, 1997).  Shopland et al. used various methods to 
demonstrate that GAF is also critical for the establishment of the pre-initiation 
complex (PIC), and the formation of a transcriptionally engaged yet paused 
RNA Pol II (Shopland, Hirayoshi, et al, 1995).  
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1.4.1 HSF1 facilitates RNA Pol II release from PIC"s 
Among eukaryotes, numerous studies have proposed that acidic 
activators participate in the formation of a pre-initiation complex (PIC) through 
the recruitment of TATA binding protein (TBP) (Xiao, Friesen, and Lis, 1995; 
Bhaumik, Raha, et al, 2004; Larschan, and Winston, 2005; Park, Werner, et al, 
2001).  This mechanism has support in S. cerevisiae because under normal 
growth conditions HSF1 occupies the promoters of many heat shock genes at 
high levels to facilitate the establishment of a functional PIC.  In flies, heat 
shock genes contain low amounts of HSF1 under normal growth conditions, a 
pre-assembled PIC, and a promoter in an "open! conformation.  It has been 
speculated that among higher eukaryotes, HSF1 competes with transcription 
factors that bind and maintain RNA Pol II molecules at the core promoter, thus 
facilitating RNA Pol II promoter escape (Mason, and Lis, 1997).    
Studies in Drosophila and mammalian cells have shown that acidic 
activators like VP16, E2F1, p53, and HSF1 can all stimulate promoter escape 
by competing with the physical interactions between RNA Pol II and 
transcription factors at the core promoter, specifically TBP and TFIIB  (Yuan, 
and Gurley, 2000; Blau, Xiao, et al, 1996; Mason, and Lis, 1997; Kadonaga, 
2004; Yankulov, Blau, et al, 1994).  Not only is it likely that HSF1 affects 
efficient promoter escape, HSF1 may also participate in subsequent steps of 
the transcription cycle such as the establishment of a paused RNA 
polymerase, the recruitment of co-activator complexes, recruitment of proteins 
kinases that modify the transcriptional machinery, and the overall maintenance 
of RNA Pol II molecules at heat inducible genes (Saunders, Core, and Lis, 
2006). 
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Figure 1.3:  Proposed role of HSF1 under !normal" (NHS) conditions and 
during heat shock conditions. (A). Under normal non-heat shock conditions 
(NHS), the Drosophila Hsp70 promoter is maintained in a nucleosome free 
"open! conformation by GAF (1). Under these conditions, HSF1 monomers (2) 
bind with rapid kinetics to the heat shock elements (HSE) binding sites.  
Together with the pre-initiation complex (3), HSF1 helps establish a 
transcriptionally engaged, yet paused RNAP II (4) 20-40 base pairs from the 
start site, an association that is stabilized by the NELF/DSIF repressor 
complex (4).  Under these conditions (NHS), basal transcriptional machinery 
fires once every ten minutes.  (B). Upon heat shock treatment, HSF1 is 
activated, resulting in homo-trimerization and stable binding to heat shock 
gene promoters (6).  Following HSF1 binding to DNA, the molecule acquires 
trans-activation competence by hyper-phosphorylation (6), resulting in the 
recruitment of co-activator complexes (i.e. Mediator or SAGA/CBP)(7), and the 
recruitment of protein kinases (8) that modify the CTD-RNAPII domain into an 
transcriptionally elongating competent form (i.e. PTEF-b), along with the 
release of negative elongation factors NELF (9).  Under these conditions, 
RNAPII pausing still occurs at +21 and +35 nt, yet RNAPII is released once 
every four seconds. 
 
 
 
 
 
 17 
 
 
 18 
1.4.2.  HSF1 promotes promoter escape during heat shock 
During non-heat shock conditions heat shock genes contain a 
transcriptionally active RNA polymerase, yet RNA Pol II is known to pause at 
positions near +21 and +35 from the Hsp70 transcription start site (Figure 
1.3A) (Rougvie, and Lis, 1988; Xiao, and Lis, 1989; O'Brien, and Lis, 1991; 
Rasmussen, and Lis, 1993; Core, Waterfall, and Lis, 2008).  Intriguingly, the 
two peaks of RNA Pol II pausing (+21 and +35) are separated by 1 turn of the 
DNA helix, suggesting that the transcriptionally engaged RNA Pol II molecules 
interact with factors also associated with one side of the DNA helix that inhibit 
effective transcription elongation, an impediment that is relieved during heat 
stress.  Under non-heat shock conditions, the repressor complex 
NELF/DSIF/Spt4-Spt5 promotes RNAP Pol II pausing at heat shock loci in 
Drosophila and human cells (Wu, Yamaguchi, et al, 2003).  Upon heat shock 
treatment, the NELF subunit is released from the Hsp70 promoter, and this 
release coincides with the subsequent recruitment of transcription elongation 
factors (DSIF, Spt4-6, PTEFb), RNA capping and processing factors which 
modify the transcriptional apparatus into a mature transcriptionally elongating 
form (Lindstrom, Squazzo, et al, 2003; Saunders, Core, and Lis, 2006).  Given 
the close proximity of NELF/DSIF/Spt4-Spt5 repressor complex with HSF1 
binding sites, it is likely that HSF1 binding to heat shock promoters induces 
NELF disassembly immediately following heat shock induction through the 
recruitment and kinase activity of PTEFb (Figure 1.3B).  
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1.4.3.  HSF1 recruitment of co-activators & chromatin remodeling 
machines to heat shock genes upon stress 
Robust heat shock gene expression requires the recruitment of co-
activator complexes that bridge interactions between HSF1 and the 
transcriptional apparatus.  The Mediator complex is a large multi-subunit 
complex that was originally identified as a yeast extract that induced basal and 
activated transcription in vitro (Kim, Bjorklund, et al, 1994).  Soon after its 
initial discovery, this complex was found to stimulate transcription from a wide 
variety of acidic activators by bridging contacts between the activators and the 
transcriptional apparatus (Conaway, Sato, et al, 2005; Fan, Chou, and Struhl, 
2006; Kim, Kwon, et al, 2004; Kim, and Lis, 2005; Kornberg, 2005; Lee, Kim, 
and Lis, 1999; Park, Werner, et al, 2001; Singh, Erkine, et al, 2006).  During 
heat shock treatment, HSF1 rapidly recruits the Mediator complex to heat 
shock genes (Figure 1.3B) (Park, Werner, et al, 2001).  Intriguingly, the rapid 
recruitment of Mediator complexes to heat shock genes depends on HSF1 
activity rather than the status of the transcriptional machinery RNA Pol II, 
indicating that Mediator recruitment precedes the establishment of an 
elongation-competent transcriptional apparatus.  This observation also directly 
questioned the "holoenzyme! hypothesis, which argues that acidic activators 
recruit pre-assembled Mediator-RNA Pol II complexes.  The fact that Mediator 
complex remains bound to promoters during active transcription strongly 
suggests that the assembly of the transcriptional apparatus occurs in a 
stepwise manner (Kornberg, 2005).  In Drosophila, it has been demonstrated 
that HSF1 interacts directly with Mediator by making contacts with the Med17, 
Med23, and Med25 subunits (Kim, Kwon, et al, 2004; Kim and Lis, 2005).  
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Because virtually all RNA Pol II transcribed genes require Mediator for basal or 
induced expression (Holstege, Jennings, et al, 1998; Kornberg, 2005), it is 
likely that HSF1 trans-activation activity at heat shock genes occurs through its 
associations with this large (~1MDa) multi-subunit complex.   
Acidic activators can influence gene expression by modifying the 
chromatin landscape of target genes via recruitment of nucleosome 
remodeling complexes (Swi/Snf) (Brown, Imbalzano, and Kingston, 1996; 
Yudkovsky, Logie, et al, 1999), the histone acetyl-transferase Spt5-Ada-Gcn5 
(SAGA) complex (Gregory, Schmid, et al, 1999; Larschan, and Winston, 2005; 
Lemieux, and Gaudreau, 2004; Zanton, and Pugh, 2004; Zanton, and Pugh, 
2006), and nucleosome methyl-transferases or ubiquitinases (Sala, La Rocca, 
et al, 2008; Shukla, Chaurasia, and Bhaumik, 2008; Smith, Petruk, et al, 
2004).  Among yeast, heat shock results in the disassembly of the TFIID pre-
initiation complex at genes that are repressed by the stress; however, genes 
that are upregulated recruit high levels of the SAGA complex (Zanton, and 
Pugh, 2004; Zanton, and Pugh, 2006).  It has been recently demonstrated that 
acidic activators recruit the multi-subunit SAGA complex through the SAGA-
Tra1 subunit (Bhaumik, Raha, et al, 2004).  Intriguingly, biochemical and 
genetic analyses demonstrate that SAGA recruitment precedes Mediator 
binding to stress-inducible genes.  It is likely that a similar mechanism exists in 
Drosophila given that, under non-inducing conditions, the Hsp70 gene is 
associated with significant amounts of the SAGA homolog TRRAP/GCN5 and 
the Mediator complex (Lebedeva, Nabirochkina, et al, 2005; Smith, Petruk, et 
al, 2004; Kim, Kwon, et al, 2004).  Furthermore, the TRRAP/GCN5 and 
Mediator complexes, like their mammalian counterparts, are dramatically 
recruited to heat shock genes by thermal stress (Lebedeva, Nabirochkina, et 
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al, 2005).  Collectively, these studies strongly suggest that these co-activator 
complexes are highly responsive to varied levels of HSF1 activity (Figure 
1.3B).   
Recently, Petesh and colleagues demonstrated that poly-ADP ribose 
polymerase (PARP) is a critical modulator of the chromatin landscape at 
Hsp70 during heat stress (Petesch, and Lis, 2008).  This novel role for PARP 
is likely due to its ability to modify, and therefore inhibit, proteins that maintain 
nucleosomes in a compact state such as histone H1 (Krishnakumar, Gamble, 
et al, 2008; Sala, La Rocca, et al, 2008).  It is likely that HSF1 recruits and 
activates PARP, the two proteins are in close proximity to transcription start 
sites, and upon heat shock, PARP becomes "activated! and redistributes over 
the entire locus.   It has been suggested that PARP facilitates RNA Pol II 
mediated gene expression by traveling along nucleosomes and exerting its 
anti-repressive effects on chromatin (Petesh and colleagues personal 
communication).  In mammals, the Hsp70 locus is modified by the activity of 
the Swi/Snf remodeling complex during heat stress (Brown, Imbalzano, and 
Kingston, 1996); however, this particular chromatin remodeling complex does 
not seem to regulate the expression of Drosophila Hsp70 (Armstrong, 
Papoulas, et al, 2002).  
 
1.4.4.  Establishment of an elongation competent transcriptional 
apparatus 
Establishment of a robust transcriptional response to heat stress 
exposure does not occur until the largest RNA Pol II subunit, Rpb1, is hyper-
phosphorylated at specific serine residues.   Hyper-phosphorylation of the C-
terminal domain (CTD) of Rpb1 is an active process that only occurs after heat 
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shock exposure (Figure 1.3B) (Saunders, Core, and Lis, 2006).  The precise 
mechanism by which activators contribute in this recruitment process is still a 
mystery; however, given the potent recruitment functions of acidic activators, it 
is likely that HSF1 plays essential roles for the recruitment of CTD kinases 
including TFIIH and PTEFb (Ni, Schwartz, et al, 2004; Schwartz, Larochelle, et 
al, 2003).  Currently, strong in vivo evidence suggests that the effective 
recruitment of PTEFb to heat shock genes depends largely on the activities of 
HSF1 and the presence of a transcriptionaly engaged yet paused RNA Pol II 
(Figure 1.3B) (Lis, Mason, et al, 2000).  Whether a direct physical interaction 
between HSF1 and the CTD kinases exists is still to be determined.  It is 
tempting to speculate that HSF1 promotes the establishment of an elongation 
competent transcriptional apparatus by modulating the activity of TF-IIB 
(Chen, and Hampsey, 2004; Lin, Ha, et al, 1991; Roberts, and Green, 1994; 
Tubon, Tansey, and Herr, 2004), the recruitment of TFIIS (Adelman, Marr, et 
al, 2005), Spt6 (Kaplan, Laprade, and Winston, 2003), or FACT (Saunders, 
Werner, et al, 2003) given that these proteins affect the intensity of heat shock 
induction.  
Dissecting the role of HSF1 on the general transcriptional machinery 
has been a difficult task because of the extremely rapid kinetics during heat 
shock.  To gain a better understanding on HSF1 role, future studies should try 
to address fundamental questions regarding the role of HSF1 activity on co-
activator interactions, and their effects on the transcriptional apparatus using 
HSF1 specific inhibitors.  For instance, is HSF1 activity necessary for the 
maintenance of co-activator interactions at promoter regions once transcription 
has already been established? How stable are these interactions? Which 
transcription factors fail to be recruited if HSF1 activity is inhibited before or 
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after heat shock induction? Does HSF1 inhibition affect the recruitment of new 
RNA Pol II molecules during heat-induced conditions?  How is the chromatin 
landscape affected by HSF1 inhibition?  Are chromatin remodeling complexes, 
PARP, or elongation factors affected by HSF1 inhibition? Are specific HSE!s 
necessary for expressing Hsp70 during basal or activated transcription?  
These questions could potentially be addressed by using small molecule 
inhibitors that modulate the heat shock response or by generating novel HSF1 
modulators that will be discussed in subsequent sections in this chapter.  
Because HSF1 is central to heat shock gene expression, and therefore, the 
general maintenance of proteome quality control, it is essential to perform 
more rigorous studies aimed at dissecting the molecular basis of HSF1-
mediated gene activation to gain a better understanding of diseases like 
cancer, neurodegenerative disorders, and natural processes like aging (Soti, 
and Csermely, 2003). 
 
1.5.  Multiple Levels of HSF1 Regulation 
HSF1 is regulated at the levels of oligomerization, DNA binding, 
phosphorylation, acquisition of trans-activation competence, sub-cellular 
localization, and co-factor interactions (Voellmy, 2004).  As mentioned 
previously, nearly all metazoans have the same general HSF1 architecture, 
with a DNA binding domain close at the N-terminus, a trimerization domain 
consisting of a series of leucine zippers (Peteranderl, and Nelson, 1992; 
Sorger, and Nelson, 1989), and a trans-activation domain close to the C-
terminus (Figure 1.1) (Green, Schuetz, et al, 1995; Shi, Kroeger, and 
Morimoto, 1995; Wisniewski, Orosz, et al, 1996; Zuo, Rungger, and Voellmy, 
1995). The first evidence that HSF1 activity was regulated at the protein level 
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came from findings where HSF1 was found to undergo structural changes 
during heat stress, resulting in a dramatic increase in molecular weight 
(Westwood, and Wu, 1993).  Later, using a wide collection of HSF1 mutants, 
the Voellmy group showed that HSF1 homo-trimerization precedes potent 
DNA binding potential (Zuo, Baler, et al, 1994).  Indeed, during heat shock 
conditions, HSF1 is rapidly activated, and transitions from a globular monomer 
to a rigid homo-trimer structure capable of binding heat shock promoter DNA 
with high affinity. Previous studies by Xiao et al. revealed that HSF1 binds to 
heat shock elements with high affinity and in a co-operative manner (Xiao, 
Perisic, and Lis, 1991).  It is likely that once activated, the relative strength of 
the HSF1-DNA interaction, is perhaps one of the strongest protein-DNA 
interactions found in nature.  Elegant structural analysis has revealed that the 
"wing! motif within the HSF1 DNA binding domain significantly contributes to 
the cooperative DNA potential of the molecule (Figure 1.2) (Littlefield, and 
Nelson, 1999).  
Due to the rapidity with which trimeric HSF1 binds to DNA (Boehm, 
Saunders, et al, 2003), the complete dissection of the early HSF1 induced 
transcriptional events has remained elusive.  Recent in vivo imaging studies 
have demonstrated in real time the potent DNA binding capacity acquired by 
HSF1 whenever cells are shifted from non-induced conditions to 37°C (Yao, 
Munson, et al, 2006).  During this transition, the dynamic association of HSF1 
to DNA under non-heat shock conditions becomes highly stable at the 
elevated temperature.  Moreover, HSF1 is rapidly redistributed from non-
specific sites on nuclei to specific heat inducible loci within the first few 
seconds after heat exposure (Westwood, Clos, and Wu, 1991; Yao, Munson, 
et al, 2006). Collectively, these experiments suggest that HSF1 transcriptional 
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activation is a stepwise, regulated process that is intimately intertwined with 
the activities of stress-sensing molecular chaperones. 
Susan Lindquist first proposed that one of the many functions of 
molecular chaperones is to inhibit HSF1 activity through a direct negative 
feedback mechanism during normal growth conditions (Lindquist, 1980).  In 
this mechanism, cells can directly "sense! heat-induced protein damage 
because heat denatured polypeptides can effectively titrate away molecular 
chaperones that normally maintain HSF1 in a monomeric “inactive” state 
(Lindquist, 1980; DiDomenico, Bugaisky, and Lindquist, 1982).  Strong 
evidence for this hypothesis was first provided by experiments that induced 
protein damage in the absence of heat stress through the addition of metal 
ions to the cell, or the direct microinjection of heat denatured proteins into frog 
oocytes (Ananthan, Goldberg, and Voellmy, 1986).  Together, these 
experiments demonstrated that artificially increasing cellular damage 
encouraged denatured proteins to sequester away those chaperones that 
inhibit HSF1 activity.   
A more precise HSF1 regulatory mechanism was proposed after initial 
studies on the role of molecular chaperones on glucocorticoid receptors 
(Nadeau, Das, and Walsh, 1993; Nair, Toran, et al, 1996).  In this regard, a 
similar Hsp90/p23/immunophilin complex that regulates GRs was also found 
to associate with the HSF1 hydrophobic regulatory regions (HR A-C, see 
Figure 1.1), and maintain HSF1 in a monomeric state (Zou, Salminen, et al, 
1998; Guo, Guettouche, et al, 2001).  This inhibitory role of Hsp90 multi-
chaperone complex on HSF1 explains the observations where Hsp90 
inhibition by geldanamycin induces HSF1 homo-trimerization and trans-
activation, Hsp90 immunodepletion from whole cell extracts results in HSF1 
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homo-trimerization and DNA binding acquisition, and Hsp90 over-expression 
effectively attenuates the heat shock response (Zou, Guo, et al, 1998; Guo, 
Guettouche, et al, 2001; Knowlton, and Sun, 2001).  In Drosophila, depletion 
of Hsp90/Hsp40/Hsp70 proteins by RNAi significantly enhances HSF1 
trimerization, induces HSF1 binding to DNA and promotes HSF1 transcription 
activation (Marchler, and Wu, 2001).  Similarly, Hsp70 binds to the HSF1 
activation domain and directly inhibits HSF1 transcription activation activity or 
"trans-activation! (Abravaya, Myers, et al, 1992; Shi, Mosser, and Morimoto, 
1998).   Moreover, proteins that regulate Hsp70 or Hsp90 can also modulate 
HSF1 transcription activation activity (Chen, et al, 1998; Dai, Zhang, et al, 
2003; Satyal).  
Acquisition of HSF1 trans-activation potential is an HSF1 regulated 
process first identified from studies using anti-inflammatory drugs like sodium 
salicylate.   In this regard, addition of sodium salicylate to eukaryotic cells 
induces HSF1 homo-trimeration, and HSF1 binding to DNA in a 
transcriptionally inactive form (Jurivich, Sistonen, et al, 1992; Westwood, and 
Wu, 1993).  It has been proposed that during heat shock, specific chaperone 
complexes modify HSF1 into becoming transcriptionally competent (Guo, 
Guettouche, et al, 2001).  Dai and colleagues found that Chip, a negative 
regulator of Hsp70 activity, associates with HSF1 during stress conditions to 
stimulate HSF1 trans-activation activity (Dai, Zhang, et al, 2003).  Moreover, 
under non-inducing conditions, cells that over-express Chip have increased 
HSF1 activity, while Chip depletion results in compromised HSF1 trans-
activation activity.  It is likely that by regulating acquisition of HSF1 trans-
activation, cells can tailor the intensity of stress response relative to the 
amount of protein damage induced by the stress.  Once heat-denatured 
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proteins are properly folded, molecular chaperones can once again bind to 
HSF1 homo-trimers and attenuate the stress response (Voellmy, 2004).   
Like most proteins, HSF1 activity is regulated by post-translational 
modifications after exposure to elevated temperatures (Larson, Schuetz, and 
Kingston, 1988; Sorger, and Pelham, 1988), and this results in slower HSF1 
electrophoretic mobility due to stress-inducible hyper-phosphorylation (Figure 
1.1).  Under non-inducing conditions, HSF1 is phosphorylated at Ser303, 
Ser307 and Ser363, and these specific modifications are known to promote 
HSF1 interactions with negative regulators such as Hsp70/Hsp40 complexes.  
During heat-shock conditions, HSF1 is hyper-phosphorylated on Ser230 and 
Thr142, and these particular modifications allow HSF1 to acquire trans-
activation competence (Holmberg, Hietakangas, et al, 2001; Holmberg, Tran, 
et al, 2002).   Intriguingly, under conditions where HSF1 is bound to DNA but 
exists in a transcriptionally inactive form, such as sodium salicylate treatment, 
Ser230 does not become phosphorylated.  To further understand this 
particular modification, Sistonen and colleagues found that expression of a 
single Ser230A HSF1 point mutant into HSF1-/- mammalian cells results in the 
induction of "mild! heat shock response whenever the cells are exposed to 
elevated temperatures (Holmberg, Hietakangas, et al, 2001), suggesting that 
other residues control the acquisition of HSF1 trans-activation competence.  
Recently, Voellmy and colleagues performed a systematic analysis of the 
phosphorylation status of HSF1 by mutating every serine, threonine or tyrosine 
to alanine, and these various point mutants were introduced into HSF1-/- cells 
to determine their ability to induce a heat shock response.  These experiments 
revealed that phosphorylation at Ser326A is critical for achieving HSF1 trans-
activation competence, while mutations at Ser121A, Ser230A, Ser292A, Ser303A, 
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Ser307A, Ser314A, Ser319A, Ser326A, Ser344A, Ser363A, Ser419A, and Ser444A are not 
as critical and result in a mild to moderate heat shock response (Guettouche, 
Boellmann, et al, 2005).  In a separate study, Kim and colleagues found that 
an HSF1 mutant harboring a Ser419A substitution prevents HSF1 from entering 
the nucleus following heat stress, resulting in loss of a heat shock gene 
induction (Kim, Yoon, et al, 2005).  Given that HSF1 is highly conserved 
among metazoans, it is likely that similar HSF1 regulatory systems exist in 
other eukaryotes.   
 
1.6.  Putative Functions of HSF1 in Mammalians 
It is widely accepted that genetic background greatly contributes to the 
phenotypic variability observed in mouse knockout studies, even within the 
same allele (Wolfer, Crusio, and Lipp, 2002).  Unlike yeast and Drosophila, 
which have a single HSF1 gene, vertebrates have multiple HSF isoforms that 
could potentially contribute to this phenotypic variability.  Our current 
understanding of the in vivo roles of each of these transcription factors arrives 
from studies using HSF knockout models.  The first HSF1 knockout animals 
contained a drug resistant cassette within the Hsf1-/- loci (Xiao, Zuo, et al, 
1999).  Strikingly, Hsf1-/- animals are viable; however these animals show 
severe developmental abnormalities, reduced size, an inability to induce heat 
shock genes or tolerate elevated heat conditions, a loss of thermotolerance 
acquisition, female infertility, and embryonic lethality.  Such developmental 
abnormalities can be compared with HSF1 defects in flies, in which Hsf4 
mutants show lethality during early stages of animal development, and 
females are infertile due to defects in oogenesis (Jedlicka, Mortin, and Wu, 
1997).  Interestingly, the observed maternal effect in Hsf4 flies or Hsf1-/- mice, 
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does not correlate with decreased levels of heat shock proteins (Christians, 
Davis, et al, 2000; Jedlicka, Mortin, and Wu, 1997).  Rather, these defects 
occur prior to the onset of zygotic gene expression, indicating that HSF1 has 
alternative functions besides regulating heat shock gene expression during 
animal development.   
The role of HSF1 during non-inducing conditions has been a topic of 
considerable debate.  In this regard, several studies demonstrate that HSF1 
regulates the basal heat shock gene expression (Murray, Whitfield, et al, 2004; 
Trinklein, Murray, et al, 2004); while other studies propose that it does not 
(Inouye, Katsuki, et al, 2003; Zhang, Huang, et al, 2002).  It is likely that such 
discrepancies are due to differences in culturing conditions or genetic 
background.  Sistonen and colleagues argue that among mammals HSF2 
facilitates HSF1 mediated gene expression (Ostling, Bjork, et al, 2007).  
However, given that Hsf2-/- mouse cells do not contain reduced Hsp levels 
under non-inducing conditions (Wang, Zhang, et al, 2003), nor are 
compromised for eliciting a heat shock response, it is likely that HSF2 is not a 
major regulator of heat shock gene transcription (Kallio, Chang, et al, 2002; 
McMillan, Christians, et al, 2002; Wang, Zhang, et al, 2003).  Instead, Hsf2-/- 
animals display severe fertility defects and large brain abnormalities while 
Hsf2-/- cells undergo heat-shock induction at lower temperature conditions 
(Kallio, Chang, et al, 2002; McMillan, Christians, et al, 2002; Paslaru, 
Morange, and Mezger, 2003; Wang, Zhang, et al, 2003).  The fact the Hsf2-/- 
cells show a heat shock response at lower temperatures may be due to the 
fact that Hsf2-/- cells are already experiencing a form of stress as shown by 
Wang and colleagues.  To date, no studies have been done to determine the 
role of HSF2 in tumor formation.  
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It is well established that HSF1-/- cells cannot induce Hsp25/27, Hsp60, 
Hsp70, Hsc70, Hsp90a & Hsp90b after heat stress exposure, making HSF1 
the primary candidate capable of inducing chaperones during stress (Inouye, 
Katsuki, et al, 2003; Zhang, Huang, et al, 2002; Xiao, Zuo, et al, 1999).  Unlike 
unicellular organisms where HSF1 controls the expression of a large 
chaperone network in response to different forms of stresses (Eastmond, and 
Nelson, 2006), mammalian HSF1 up-regulates only few subsets of genes that 
are specific to each type of stress condition (Murray, Whitfield, et al, 2004; 
Trinklein, Murray, et al, 2004).  It is possible that higher organisms have 
evolved novel methods of coping with specific types of stress by utilizing novel 
chaperone system networks that can cope with the damage induced by the 
stress (Csermely, 2008; Palotai, Szalay, and Csermely, 2008).  Furthermore, 
because multi-cellular organisms are composed of different tissue and organ 
systems, each cell type has adopted specific functions to deal with the specific 
stresses (i.e. liver-detoxification of exogenous compounds, kidneys and 
intestines-maintenance of osmotic balance, skin-protects against UV exposure 
and external chemical agents etc).  Thus, the total "stress! burden is distributed 
among many tissues, and not solely placed on any particular cell.  Overall, 
because cancer is a general stress inducing disorder, it appears that HSF1 
regulates the basal level expression of molecular chaperones that allow 
transformed cancer cells to cope with stress. 
 
1.7.  Thermotolerance: Protection from Cellular Damage by Molecular 
Chaperones 
The best examples of the cytoprotective actions of molecular 
chaperone come from thermotolerance studies (Lindquist, and Craig, 1988b; 
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Parsell, and Lindquist, 1993).  In these studies, an organism is rapidly killed by 
heat exposure when it is switched from its normal growth conditions to 
extreme temperatures.  However, organisms that have had been given mild 
preheat treatments, and thus contain higher amounts of Hsp's, survive the 
lethal heat exposure at much higher rates.  Remarkably, heat pre-conditioning 
also allows the host to tolerate other forms of stresses, such as exposure to 
heavy metals, reactive-oxygen species (ROS), or hypoxia. With the exception 
of ionizing radiation, all forms of stresses results in increased levels of 
molecular chaperones (Anderson, Herman, et al, 1988), a fact that provides 
strong support for the hypothesis that molecular chaperones induce 
cytoprotection in response to a wide variety of stress conditions (Morimoto, 
1998; Li, and Werb, 1982).   
In yeast, the major proteins associated with thermotolerance acquisition 
include members of the Hsp100 family.  Not surprisingly, exposure of 
preconditioned Hsp104-/- cells to a lethal heat shock (~50°C) results in the 
formation of large protein aggregates and a thousand-fold increase in cell 
death compared to wild-type cells under the same conditions (Sanchez, and 
Lindquist, 1990; Sanchez, Parsell, et al, 1993).  Interestingly, antibodies 
targeted to yeast Hsp104 protein also recognize heat inducible proteins in E. 
coli and mammals (Parsell, Sanchez, et al, 1991).  In mammals, Hsp110-/- 
knockouts have not yet been generated; however, overexpression of Hsp110, 
the mammalian Hsp104 homolog, results in an increased capacity to survive 
lethal heat shock exposures (Oh, Chen, and Subjeck, 1997).   
In mammals, Hsp70 protein has been shown to be critical for 
thermotolerance acquisition (Lee, Kwon, et al, 2004).  In this regard, adult 
Hsp70-/- animals show extreme heat sensitivity and display a dramatic 
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tendency to undergo apoptosis, a fact that will be discussed further in section 
1.8 below.  Similarly in Drosophila, Hsp70 is essential for thermotolerance 
acquisition, as animals deleted of all six copies of Hsp70 genes do not acquire 
thermotolerance upon repeated stress exposure and cannot survive extreme 
heat shock exposures (Gong, and Golic, 2006; Sanchez, and Lindquist, 1990; 
Welte, Tetrault, et al, 1993).  Currently many of the molecular events regarding 
thermotolerance acquisition are still not fully understood.  It is tempting to 
speculate that thermotolerance acquisition depends on the concerted actions 
of Hsp110 and Hsp70, given that Hsp70 over-expression stabilizes Hsp104 
(Sanchez, Parsell, et al, 1993), and that both proteins have been found to 
work together in the protein refolding pathway (Oh, Chen, and Subjeck, 1997). 
 
1.8.  Heat Shock Proteins are Molecular Chaperones that Catalyze 
Protein Folding Reactions 
Much of the current biochemical understanding of the activities and 
intermolecular interactions of molecular chaperones arise from in vitro 
experiments in which heat denatured polypeptides are incubated with various 
chaperones, and the activities, or structural status of the "re-natured! 
polypeptides are subsequently analyzed (Buchner, Schmidt, et al, 1991; 
Jakob, Gaestel, et al, 1993; Skowyra, Georgopoulos, and Zylicz, 1990; Wiech, 
Buchner, et al, 1992).  In general, these studies demonstrated that the heat 
shock proteins Hsp27, Hsp60, Hsc70, Hsp90 and Hsp110 are capable of 
binding heat-denatured polypeptides and maintaining them in a "folding-
competent! state.  However, complete protein renaturation does not occur until 
Hsp70 is recruited to the complex (Freeman, and Morimoto, 1996).   
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1.8.1.  The Hsp70 family:  
During heat stress conditions, nearly all organisms over-express Hsp70 
proteins.  Strikingly, Hsp70 shows greater than 50% conservation among most 
living systems, primarily within the ATPase domain, and the peptide 
recognition domain (Lindquist, and Craig, 1988a; Hendrick, and Hartl, 1993).  
Our current understanding of the biochemical activities of Hsp70 stems from in 
vitro studies performed using purified DnaK protein isolated from E. coli 
(Bardwell, and Craig, 1984; Friedman, Olson, et al, 1984).  DnaK, like Hsp70 
proteins in higher organisms, is heat inducible and catalyzes protein-folding 
reactions in an ATP dependent manner by binding to exposed hydrophobic 
residues (Pelham, 1986; Rudiger; Skowyra, Georgopoulos, and Zylicz, 1990; 
Schumacher, Hurst, et al, 1994; Schumacher, Hansen, et al, 1996; Freeman, 
and Morimoto, 1996;  Buchberger, and Bukau, 1997).  
Interestingly, members of the Hsp70 gene family have undergone 
several gene duplication events.  In S. cerevisiae, at least nine genes related 
to the Hsp70 family have been identified whose expression levels change in 
response to growing temperatures.  In particular, the two main heat inducible 
Hsp70 isoforms are encoded by the SSA3 and SSA4 genes: both are 
expressed at low levels during normal growth conditions (23°C), and are 
dramatically up-regulated after heat stress (39°C) (Werner-Washburne, Stone, 
and Craig, 1987).  Drosophila contains approximately 5-6 copies of Hsp70, as 
well as 7 other related genes that are abundantly expressed under normal 
growth conditions called heat shock cognate proteins (HSC!s) (Wadsworth, 
1982).  Mammals express five Hsp70 family proteins: Hsp70, Hsp72, p72, 
Grp78 and a mitochondrial specific Hsp70 isoform.  The Hsp70 protein is 
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moderately expressed under normal growth conditions, is induced mildly by 
heat shock, and is commonly referred to in the literature as the "72k-heat 
shock protein! (Milarski, and Morimoto, 1986; Welch, and Feramisco, 1984).  
Hsp72 is strictly heat shock induced, and is referred to as Hsp70 (Hsp70A1A).  
The p72 protein is expressed at high levels in growing cells, while Grp78 is 
expressed at high levels under normal growth conditions and is commonly 
referred to as Bip (Watowich, and Morimoto, 1988).  In the mitochondria, 
mHsp70 is expressed at high levels under normal growth conditions and is not 
heat inducible.  Given the high degree of evolutionary conservation among 
Hsp70 proteins, it is not surprising that these HSP70 family members perform 
similar reactions within distinct cellular compartments: the endoplasmic 
reticulum lumen for GRP78, the cytoplasmic and nuclear compartments for 
p72, Hsp70, and Hsp72, and the mitochondria specific mHsp70.  In yeast, any 
of the Hsp70 members (SSA1-4) can partially complement one another, thus 
further demonstrating the high degree of functional conservation among this 
family of proteins (Werner-Washburne, Stone, and Craig, 1987).  To date, it is 
unknown whether the various mammalian Hsp70 isoforms can compensate for 
the loss of each other. 
 
1.8.2.  Refolding of heat denatured polypeptides by molecular 
chaperones  
Protein refolding is an energy consuming reaction catalyzed by 
molecular chaperones.  First, the unfolded protein substrate is delivered to the 
Hsp70 folding machinery by Hsp90/Hsp40 multi-chaperone complexes (Figure 
1.4) (Michels, Kanon, et al, 1997; Takayama, Bimston, et al, 1997; Wiech, 
Buchner, et al, 1992).  Binding of Hsp90/Hsp40 holds the unfolded protein 
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substrate in a conformation-competent state that awaits the arrival of Hsp70 
(Schneider, Sepp-Lorenzino, et al, 1996; Wiech, Buchner, et al, 1992).  In this 
regard, the heat denatured polypeptide/Hsp90/Hsp40 complex is brought to 
Hsp70 through the assembly of the scaffolding protein, Hop (Hsc70/Hsp90 
organizing protein) (Pratt, and Dittmar, 1998) that recognize Hsp70 in an ADP 
bound form (Johnson, Schumacher, et al, 1998).  Interestingly, Hop does not 
exhibit any chaperoning activity on its own, but rather induces protein 
renaturation by effectively bridging the interactions between the heat 
denatured polypeptide/Hsp90/Hsp40 complex and Hsp70 (Johnson, 
Schumacher, et al, 1998; Prapapanich, Chen, and Smith, 1998).  Once Hsp90 
is within close proximity to Hsp70, the denatured substrate is passed to Hsp70 
by Tpr-2 co-chaperone (Brychzy, Rein, et al, 2003) and Hsp70 catalyzes the 
refolding process by hydrolyzing ATP.  Once the protein substrate has been 
completely folded, it is released from the chaperone complex.  First, Hsp40 is 
released from the multi-protein complex, followed by the recruitment of Bag1, 
Chip and HSBP1 (Zylicz, LeBowitz, et al, 1983; Chappell, Welch, et al, 1986; 
Buchberger, Valencia, et al, 1994; Buchberger, Theyssen, et al, 1995).  These 
latter factors stabilize Hsp70 in an inactive, ADP bound form, resulting in the 
efficient release of the polypeptide from the Hsp70 chaperone complex.  
Interestingly, binding of Bag1/Chip/HSBP1 to the unfolded substrate or 
substrates affects the "fate! of the polypeptide since those proteins that cannot 
be properly folded due to extreme damage are quickly targeted for degradation 
via the ubiquitin dependent proteosome pathway (Demand, Alberti, et al, 
2001).  Intriguingly, besides its role in protein re-folding, strong evidence 
suggests that Hsp70 is critical for the transport of proteins across lipid  
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Figure 1.4:  Protein Folding Pathway Mediated by Molecular Chaperones.  
Upon exposure to elevated temperatures, properly folded proteins (blue lines) 
become denatured (black lines)(1), and this results in the exposure of 
hydrophobic residues that are otherwise buried deep within the protein core.  
These heat-denatured polypeptides are quickly bound by molecular 
chaperones that maintain the proteins in a folding competent state (2) (i.e. 
Hsp90 & Hsp40).  Binding of a scaffolding protein, Hop (3) to the Hsp90/40 
chaperone complex promotes the recruitment of the folding apparatus, Hsp70 
(4).  Tpr-2 binding (5) to the multi-chaperone complex induces the release of 
Hsp90, and the passage of the heat denatured protein to Hsp70 (6).  Once the 
polypeptide enters Hsp70 catalytic core, Hsp70 induces protein renaturation 
through the hydrolysis of ATP (7).  After Hsp70 finishes refolding the 
polypeptide, and Hsp40 is released from the chaperone complex (8), followed 
by the subsequent recruitment of Bag, Chip and HSPB1 (9).  Bag, Chip and 
HSPB1 maintain Hsp70 in a catalytically inactive (ADP) bound form.  
Depending on the status of the protein, Bag/Chip/HSPB1 determine the fate of 
the "renatured! polypeptide.  If the damage is too severe, and the protein 
cannot be properly folded, it is targeted to degradation via the ubiquitin 
dependent proteosome pathway.  However, if the refolding reaction is 
successful (blue lines), the polypeptide is released from the chaperone 
complex (10).  
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membranes.  Here, Hsp70 promotes protein-unfolding reactions before 
polypeptides can be transported across specific organelles (Deshaies, Koch, 
et al, 1988).  In S. cerevisiae, the Grp78 homolog Kar2p temperature sensitive 
mutant contains high levels of partially translocated proteins caught in the act 
of passage through lipid membranes at the non-permissive temperature 
(Nguyen, Law, and Williams, 1991; Sanders, Whitfield, et al, 1992).  
Recently, it has been found that the Hsp27 small heat shock protein 
family also facilitates the protein refolding processes by breaking apart pre-
existing protein aggregates that accumulate during cellular stress (Kampinga, 
Brunsting, et al, 1994).  Hsp27 maintains these “broken” polypeptides in a 
conformation-competent state (Jakob, Gaestel, et al, 1993), and protein 
renaturation occurs when Hsp70 is recruited to the complex (Ehrnsperger, 
Graber, et al, 1997).  Similarly, the Hsp110 large heat shock protein family is 
known to promote refolding reactions by binding to heat denatured 
polypeptides and maintaining them in a conformation-competent state that 
requires subsequent Hsp70 activity (Oh, Chen, and Subjeck, 1997). 
 
1.9.   Regulation of Pro-survival Signaling Cascades by Hsp90/Hsp70 
Chaperone Complexes 
Cancer is a disease of genetic instability, and while only a few 
mutations have shown to induce tumor formation, mature tumors have been 
shown to contain over 10,000 mutations at the time of diagnosis (Stoler, Chen, 
et al, 1999; Hahn, and Weinberg, 2002).   Due to this high mutation rate, 
cancer cells have the ability to evade therapeutic treatment through the 
selection of drug resistant clones that are often associated with cancer relapse 
(La Rosee, Corbin, et al, 2002).  Weinberg and colleagues suggest that during 
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cellular transformation, cells generally acquire six general characteristics: (1) 
self-sufficiency in growth signaling, (2) insensitivity to anti-growth signaling, (3) 
the ability to evade apoptosis, (4) sustained angiogenesis, (5) the ability to 
invade surrounding tissues and undergo metastasis, and (6) limitless 
replication potential (Hanahan, and Weinberg, 2000).  Because of these 
general features, cancer cells have the capacity to survive extreme 
environmental conditions and therefore can colonize adverse 
microenvironments.  Given the general adaptability to stress conditions, it is 
not surprising that cancer cells have an increased requirement for chaperone 
activity relative to non-cancerous cells, and indeed cancer cells have elevated 
amounts of heat shock proteins (Becker, Multhoff, et al, 2004).  Previous 
attempts at isolating inhibitors targeting various molecular chaperones has 
resulted in failure, and has succeeded only for the Hsp90 family, 
geldanamycin and its derivatives (17-AAG and DMAG) (Whitesell, Mimnaugh, 
et al, 1994).  In spite of this, it is now accepted that Hsp90 regulates the 
stability of proteins that promote each of the classical hallmarks of cancers: 
Her2, CDK!s, Akt, Src, VEGF, Erb, and telomerase (An, Schulte, and Neckers, 
2000; Bagatell, and Whitesell, 2004; Chiosis, Vilenchik, et al, 2004; Goetz, 
Toft, et al, 2003; Workman, 2004; Zhang, and Burrows, 2004).  In most cases, 
Hsp90 inhibition induces the degradation of its client proteins, thus strongly 
suggesting that many of the mutated proteins that often promote cellular 
transformation are stabilized by the general activities of molecular chaperones 
(An, Schulte, and Neckers, 2000; Neckers, 2002; Mimnaugh, Xu, et al, 2004). 
In the clinical setting, analyzing the levels of Hsp90 has become a good 
prognostic indicator of cellular transformation and metastatic potential of 
cancerous cells (Eustace, Sakurai, et al, 2004).  Furthermore, Hsp90 inhibition 
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has been shown to greatly improve radiation sensitization (Bisht, Bradbury, et 
al, 2003), and increase the effective treatment of anaplastic cell lymphomas 
(Bonvini, Gastaldi, et al, 2002), acute myeloid leukemia (Minami, Kiyoi, et al, 
2002), chronic myelogenous leukemia (Gorre, Ellwood-Yen, et al, 2002), 
prostate cancer (Vanaja, Mitchell, et al, 2002), as well as decrease metastasis 
in brain glioblastoma cells (Zagzag, Nomura, et al, 2003).  Unfortunately, 
pharmacological Hsp90 inhibition also activates osteoclast c-Src signaling and 
promotes the invasion of prostate carcinoma cells in bone tissues (Yano, 
Tsutsumi, et al, 2008).  Also, Hsp90 inhibition is known to induce 
cytoprotection by increasing expression levels of the anti-apoptotic factor 
Hsp70 (Bagatell, Paine-Murrieta, et al, 2000; Gabai, Budagova, and Sherman, 
2005).  In spite of these adverse effects, the Hsp90 inhibitors 17AAG and 
DMAG have reached phase II clinical trials, and are currently used in 
combination with other anti-cancer drugs during therapy.  In this way, the in 
vivo efficacy of conventional chemotherapeutic drugs show dramatic 
improvements, resulting in an overall increase in the number of successfully 
treated cancer patients. Overall, it is becoming more evident that molecular 
chaperones maintain proteins that promote cellular transformation and 
tumorigenesis in humans. 
 
1.9.1  Chaperone maintenance of ligand-activated trans-membrane 
receptors which promote cellular transformation: 
The first insights that molecular chaperones affected ligand-activated 
hormone receptors came from findings that revealed that Hsp90 multi-
chaperone complexes regulate the stability, ligand responsiveness, trafficking, 
and turnover rate of glucocorticoid receptors (GRs) (Catelli, Binart, et al, 1985; 
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Sanchez, Toft, et al, 1985; Schuh, Yonemoto, et al, 1985; Picard, Khursheed, 
et al, 1990).  Together, Hsp90/70 maintain GRs in a ligand "open! state to 
become highly sensitive to fluctuating glucocorticoid hormone levels (Bresnick, 
Dalman, et al, 1989; Hutchison, Dittmar, and Pratt, 1994; Nair, Toran, et al, 
1996; Pratt, and Dittmar, 1998).  Upon hormone binding, GR undergoes 
structural changes that result in GR binding to DNA and the subsequent 
induced expression of glucocorticoid responsive genes (Elbi, Walker, et al, 
2004; Pratt, Galigniana, et al, 2004).  At the plasma membrane, Hsp90/Hsp70 
co-chaperone complexes also prevent GR from becoming targeted for 
degradation (Whitesell, and Cook, 1996; Bercovich, Stancovski, et al, 1997).   
This type of chaperone-mediated cell signaling control extends beyond the 
realm of GR receptors and includes other trans-membrane receptors, growth 
factors receptors, and non-receptor tyrosine kinases (Bardelli, Longati, et al, 
1996).  In many forms of cancers, the VEGF and ErbB-2 receptors exist in an 
abnormal conformation that require Hsp90 and Hsp70 activity (Le Boeuf, 
Houle, and Huot, 2004; Citri, Gan, et al, 2004; Kim, Chao, et al, 2004; Xu, 
Mimnaugh, et al, 2001).   
 
1.9.2.  Chaperone maintenance of non-receptor tyrosine kinases: 
The first protein kinase found to be regulated by molecular chaperones 
was the viral oncogene v-Src (Brugge, Erikson, and Erikson, 1981; 
Oppermann, Levinson, et al, 1981).  Upon viral infection, v-Src binds Hsp90 
and uses its chaperoning activity to promote the folding, stability, and 
assembly of viral proteins.  Intriguingly, these studies found that Hsp90 is one 
of the most abundant molecular chaperones present under normal growth 
conditions, comprising ~1-2% the total protein content (Brugge, Erikson, and 
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Erikson, 1981; Oppermann, Levinson, et al, 1981).  Since then, Hsp90 has 
been found to bind, and therefore regulate, hundreds of other signaling 
proteins (Pratt, and Toft, 2003), including but not limited to Raf, CK2, PKR, 
Ste11, CDK4 and IKK (Miyata, and Yahara, 1992; Cutforth, and Rubin, 1994; 
Van der Straten, Rommel, et al, 1997; Powers, Clarke, and Workman, 2008).  
Many of these Hsp90 client proteins have diverse functions and have been 
shown to be critical for viral infection, maintenance of cell proliferation, and 
apoptosis inhibition (Miyata, and Yahara, 1992).   
 The Raf oncogene, a component of the mitogen activated signaling or 
MAPK pathway, is a classic Hsp90 client protein.  Using a genetic approach, 
Cutforth and colleagues found that Hsp90 modulates the MAPK signaling 
pathway in Drosophila (Cutforth, and Rubin, 1994; Van der Straten, Rommel, 
et al, 1997), and it was soon discovered that Hsp90 controls Raf mediated 
signaling activity in mammals as well (Grammatikakis, Lin, et al, 1999).  Not 
relevant to protein kinases, but often found in a "misfolded! conformation in 
many cancers, is the tumor suppressor protein p53.  Interestingly, 
maintenance of the misfolded p53 mutants also requires Hsp70/Hsp90 
chaperoning activity (Blagosklonny, Toretsky, et al, 1996; Pinhasi-Kimhi, 
Michalovitz, et al, 1986).   
Overall, these studies suggest that Hsp90 multi-chaperone complexes 
regulate the signaling activity of pro-survival pathways.  Therefore, future 
studies should focus on generating novel classes of inhibitors that effectively 
disrupt specific Hsp90 co-chaperone interactions present in transformed 
cancer cells (Kamal, Thao, et al, 2003; Powers, Clarke, and Workman, 2008).  
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1.10.  Molecular Chaperones Antagonize Apoptotic Signaling Cascades 
at Multiple Levels 
Apoptosis is a naturally occurring process that organisms use to 
destroy unwanted cells in developmental processes like removal of 
supernumerary cells in the Drosophila eye, formation of limb buds in 
mammals, and is the main elicitor of cell death by anti-cancer drugs in 
humans.  Depending on the initiating apoptotic stimuli, the external-death 
receptor pathway (Fas or TNF-a ligand activation) (Nagata, 1997), or 
mitochondria dependent signaling pathway (Li, Nijhawan, et al, 1997), the 
outer mitochondria membrane becomes permeable resulting in the release of 
various proteins that normally reside within the intermembrane space such as 
cytochrome-c, AIF-apoptotic inducing factor, and Smac/Diablo-caspase 
activating factors.  Once in the cytosol, cytochrome-c induces formation of the 
apoptosome complex by inducing Apaf-1 dimerization and the recruitment of 
procaspase-9 (Li, Nijhawan, et al, 1997).  Subsequently, the apoptosome 
activates a series of pro-caspase proteins that ultimately result in caspase-3 
activation.  Caspase-3 induces the cleavage of endogenous cellular proteins 
that results in loss of the integrity of lipid membranes, chromosome 
fragmentation, and, ultimately, cell death.   
The regulation of cell survival by molecular chaperones has been the 
source of considerable debate; however, it is clear that molecular chaperones 
promote cell survival by attenuating apoptotic signaling at multiple levels 
(Figure 1.5).  One protein in particular that has elicited some controversy 
regarding its function in apoptosis regulation is Hsp70.  In this regard, it has 
been argued that the primary function of Hsp70 is to inhibit the apoptosome by 
interfering with Apaf-1 dimerization and procaspase-9 recruitment (Beere, 
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Wolf, et al, 2000).  In contrast, Steel and colleagues argue that Hsp70 acts 
further upstream of the pathway by regulating cytochrome-c release from the 
mitochondria (Steel, Doherty, et al, 2004).  Contrary to both of these reports, 
the Egeblad group argue that Hsp70!s primary role does not involve 
cytochrome-c or apoptosome formation but rather the final signaling events, as 
well as maintaining procaspase-3 in an inactive form (Jaattela, Wissing, et al, 
1998).  Besides regulating the internal mitochondrial dependent apoptosis 
signaling pathway, Hsp70 has also been found to regulate the activity of death 
receptors TNF-! and Fas (Guo, Sigua, et al, 2005; Scaffidi, Schmitz, et al, 
1999), which normally elicit apoptosis whenever a specific ligand binds to the 
extra-cellular ligand-binding domain (Figure 1.5).  Once activated, death 
receptors recruit scaffolding proteins including Daxx, FADD, TRADD, and RIP, 
that are necessary for the recruitment and activation of procaspase-8.  
Procaspase-8 activation induces the release of cytochrome c from the 
mitochondria through Bid (Scaffidi, Schmitz, et al, 1999).  Recently, it has been 
found that Hsp70 inhibits the ligand responsiveness, assembly of scaffolding 
proteins, and general signaling activity of death receptors in leukemia cells  
(Guo, Sigua, et al, 2005).  Not surprisingly, Hsp70-/- derived cell lines undergo 
apoptosis at extremely high frequencies (Lee, Kwon, et al, 2004).  Collectively, 
these studies indicate that the high Hsp70 levels observed among various 
cancers contribute to their survival by efficiently attenuating pro-apoptotic 
signaling, a classic hallmark of cancer cells. 
The Hsp27 heat shock proteins, whose main function generally 
correlates with the disassembly of protein aggregates, and maintaining 
cytoskeleton integrity, has recently been shown to affect both the intrinsic and 
extrinsic apoptotic signaling pathways as well (Figure 1.5) (Charette, Lavoie,  
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Figure 1.5:  Regulation of apoptosis signaling pathways by molecular 
chaperones.  Molecular chaperones inhibit both stress induced intrinsic, or 
death receptor mediated extrinsic apoptotic signaling pathways at multiple 
levels.  Black arrows: induction; Red hatch: inhibition.  *Note:  Hsp90 stabilizes 
AKT, and this results in apoptosome inhibition (Apaf-9).  
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 et al, 2000; Ehrnsperger, Graber, et al, 1997).  In particular, Hsp27 inhibits 
apoptosis by the sequestring of cytochrome c from the mitochondria (Bruey, 
Ducasse, et al, 2000), the inhibition of apoptosome assembly (Garrido, Bruey, 
et al, 1999), and the Daxx death receptor scaffold proteins (Charette, Lavoie, 
et al, 2000), and the sequestrating free-radicals and reactive oxygen species 
(ROS) (Mehlen, Kretz-Remy, et al, 1996).  Interestingly, Hsp27 negatively 
regulates apoptosis as a large Hsp27 oligomeric complex (~1MDa) (Garrido, 
Bruey, et al, 1999; Bruey, Paul, et al, 2000).  In mice, Hsp27 over-expression 
increases the tumorigenicity of rat colon cancer cells by effectively attenuating 
the death response (Garrido, Fromentin, et al, 1998).  In human prostate 
cancer cells, Hsp27 RNAi depletion results in effective induction of apoptosis 
(Rocchi, So, et al, 2004), while injection of human breast cancer cells over-
expressing Hsp27 into nude mice results in the formation of high-grade 
metastatic nodules (Lemieux, Oesterreich, et al, 1997). 
Hsp90 displays intrinsic anti-apoptotic activity (Beere, Wolf, et al, 2000), 
as it can bind to and inhibit apoptosome complex formation (Apaf-1 
dimerization), as well as inhibit procaspase-9 recruitment (Figure 1.5) 
(Pandey, Saleh, et al, 2000).  However, relatively little is known about Hsp90!s 
role in regulating components of the apoptotic signaling pathway.  Instead, it is 
believed that Hsp90 exerts its general anti-apoptotic functions by maintaining 
proteins involved in cell survival signaling pathways (i.e. MAPK) that attenuate 
apoptotic-signaling through "cross-talk! signaling interactions.  In this regard, 
its been shown that Hsp90 inhibition by 17-AAG & DMAG decreases AKT 
activity; AKT is known to maintain caspase-9 in an inactive state (Figure 1.5) 
(Basso, Solit, et al, 2002; Cardone, Roy, et al, 1998).  Unlike Hsp70-/- derived 
cell lines, a true genetic analysis involving Hsp90!s role in apoptosis has not 
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been performed since Hsp90-/- mice fail to survive beyond the 10th day of 
gestation (Voss, Thomas, and Gruss, 2000).  Overall, the fact that cancer cells 
have increased levels of heat shock proteins, in particular Hsp70 and Hsp90 
(Becker, Multhoff, et al, 2004; Nanbu, Konishi, et al, 1998), together with the 
fact that their inhibition greatly predisposes cancer cells to pharmacological 
treatment, emphasizes the importance of novel Hsp inhibitors aimed at 
developing more effective cancer therapies (Basso, Solit, et al, 2002; Bisht, 
Bradbury, et al, 2003; Jaattela, Wissing, et al, 1998; Nanbu, Konishi, et al, 
1998; Powers, Clarke, and Workman, 2008; Soti, Nagy, et al, 2005; Wei, 
Zhao, et al, 1994; Zaarur, Gabai, et al, 2006).   
 
1.11.  Modulation of the Heat Shock Response by Exogenous 
Compounds 
Having elevated amounts of heat shock proteins allow cells to better 
cope with the protein damagade induced by various forms of stress, and over 
time, the beneficial functions of heat shock proteins has become apparent to 
humans.  Its been suggested that societies that practice sauna as a method of 
socializing tend to retard the aberrant effects of aging, and societies that use 
sauna extensively are thought to "age-better!.  Intriguingly, the mild increases 
in temperature during the sauna process result in stress "preconditioning!, 
resulting in increased levels of molecular chaperones (Soti, and Csermely, 
2003).  Besides heat, a person!s diet can dramatically affect the amount of 
heat shock proteins present in the system; for instance, consumption of large 
quantities of amino acids such as glutamine or metals ions such as Cu+2, 
Mn+2, and Zn+2, can also result in increased levels of heat shock proteins.  In 
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mammals, zinc levels typically decrease during aging, and this event coincides 
with reduced levels of Hsc70, Hsp40 and Hsp60 proteins (Soti, and Csermely, 
2003).  Under these conditions, zinc depletion causes a dramatic increase in 
protein aggregates compared with same aged animals whose diet is 
supplemented with zinc.  Similarly, caloric restriction is known to slow the 
aging process and elevate molecular chaperone levels.  Diets that have 
increased levels of curcumin, a natural spice often found in Indian cuisine, 
increases endogenous Hsp70 levels (Khar, Ali, et al, 2001).  Intriguingly, 
consumption of curcumin induces cytoprotection among normal cells yet 
induces apoptosis among a variety of cancer cell lines.  However, studies 
show that curcumin treatment results in the clonal selection of drug resistant 
cancer cells that contain elevated heat shock proteins.  
Small organic molecules can also modulate the heat shock response.  
In particular, the Hsp90 inhibitors geldanamycin and radicol can induce heat 
shock gene expression when administered at low doses (Zou, Guo, et al, 
1998; Koga, Xu, et al, 2006).  Alternatively, as mentioned previously, the anti-
inflammatory drug sodium salicylate effectively inhibits HSF1 trans-activation 
activity (Jurivich, Sistonen, et al, 1992; Westwood, and Wu, 1993).  Recently, 
the naturally occurring compound, triptolide, has been found to attenuate the 
heat shock response.  Because triptolide does not prevent HSF1 DNA binding, 
it is suggested that this drug inhibits the HSF1 activation domain or another 
component of the general transcriptional apparatus (Westerheide, Kawahara, 
et al, 2006).  In any event, studies that utilize triptolide may reveal hidden 
properties of HSF1, or the transcriptional machinery, during the transcription 
cycle. 
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Other mechanisms that affect transcription regulation include a class of 
small non-coding RNA's (B2 RNA) transcribed by RNA polymerase III that are 
induced during heat shock conditions.  In this mechanism, heat stress results 
in the expression of B2 RNA from interspread regions within the mouse 
genome thought previously to be "junk DNA! (Allen, Von Kaenel, et al, 2004; 
Espinoza, Allen, et al, 2004).  Expression of B2 RNA inhibits elongating 
competent RNA Pol II molecules at non-heat shock inducible genes witout 
affecting heat-shock loci.  Whether a similar gene regulatory mechanism exists 
among other eukaryotes is still unknown. 
 
1.12.  Novel Uses of Aptamers in Basic and Clinical Applications  
Aptamers have emerged as promising reagents for dose-dependent 
modulation of protein activities both in vitro and in vivo.  Aptamers are single-
stranded DNA or RNA molecules that inhibit specific molecular surfaces by 
binding to their target via ionic, hydrophobic and hydrogen bond interactions.  
They are isolated through an iterative process of selection and amplification 
called Systematic Evolution of Ligands by EXponential enrichment (SELEX) 
(Ellington, and Szostak, 1990; Tuerk, and Gold, 1990) from combinatorial 
libraries containing approximately 1X1015 different molecules.  The large 
sequence complexity associated with such a starting library ensures the best 
opportunity the isolate of high affinity aptamers to various types of molecular 
surfaces, ranging from single small molecules (Sazani, Larralde, and Szostak, 
2004) to distinct functional domains on a single protein (Shi, Fan, et al, 2007).   
To generate RNA aptamers, the SELEX experiment starts with a large 
randomized sequence pool containing 1014-1016 different species that fold into 
different shapes determined by their different sequences. This pool is then 
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subjected to iterative cycles of selection and amplification.  In each cycle, a 
target, such as a protein molecule, is used to select from the pool of RNA 
molecules that bind it.  Following the separation of the bound RNA from the 
unbound, the bound fraction is amplified by RT-PCR to generate a new pool 
for the next cycle.  Usually RNA aptamers with the highest affinity for the 
target protein will dominate the population in 8-12 rounds.  At the end of the 
process, the enriched aptamers are cloned and sequenced for further 
characterization. The aptamers generated by this process are capable of 
binding to a wide variety of targets with high affinity and specificity.  To date, 
both DNA and RNA aptamers have been found to bind their targets with 
dissociation constants (Kd) in the low nanomolar or picomolar range, and can 
discriminate between proteins that share common structural features (Fan, 
Shi, and Lis, 2005; Sevilimedu, Shi, and Lis, 2008). 
In recent years, its been demonstrated that RNA aptamers can be 
expressed in vivo under tight genetic control (Shi, Hoffman, and Lis, 1999), 
and that they can assert their effect within specific cells, tissues or 
developmental stages without eliciting an immune response in the targeted 
organism (White, Sullenger, and Rusconi, 2000).  Our lab first pioneered the in 
vivo application of aptamers by targeting the Drosophila B52 protein.  In this 
model system, we demonstrated that Drosophila B52 can be specifically 
inhibited in vitro and in vivo using a multivalent inhibitory aptamer RNA 
(iaRNAB52) (Shi, Hoffman, and Lis, 1999).  This iaRNAB52 binds B52 avidly, 
inhibits B52-stimulated pre-mRNA splicing in vitro, and suppresses all 
abnormal phenotypes caused by B52 over-expression in vivo.  Since its initial 
demonstrated application, this method has been regarded as an effective 
therapeutic model and a novel approach to drug target validation (Famulok, 
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and Mayer, 1999; Pendergrast, Marsh, et al, 2005).  In addition to their 
widespread utility as molecular probes in basic research (Fan, Shi, and Lis, 
2005; Sevilimedu, Shi, and Lis, 2008), aptamers are quickly becoming used in 
the clinical setting (Blind, Kolanus, and Famulok, 1999; Bock, Griffin, et al, 
1992; Csaky, 2003; Famulok, Blind, and Mayer, 2001; Lee, Canny, et al, 
2005), thus demonstrating their broad utility as molecular inhibitors.  Notably, 
an aptamer targeting NF-#B was recently expressed in cancer cell lines as 
well as a murine xenograft model and displayed significant anti-tumor activity 
(Mi, Zhang, et al, 2006).   Therefore, to further understand HSF1 function 
during animal development and its role in tumor maintenance, I used the RNA 
aptamer technology in a chemical-genetic approach to inhibit HSF1 activity in 
both human cancer cells and Drosophila.  
 
1.13. Concluding Remarks 
Eliciting an effective heat shock response allows cells to survive 
adverse conditions.  Because of this, it is not surprising that this response 
became an integral component of living systems early during evolution.  
Intriguingly, rapidly evolving systems like cancer cells continue to exploit the 
benefits provided by molecular chaperones during processes such as cellular 
transformation and deregulated cancer growth.  As the multiple functions of 
molecular chaperones become better understood, it is clear that in order to 
combat diseases like cancer, we must be able to effectively disrupt those 
molecular chaperones that maintain cancer cell survival.  Only by 
systematically inhibiting the entire chaperone network will we be able to 
understand how each of these proteins contribute toward the general 
maintenance of the transformed phenotype associated with cancer.  Using this 
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knowledge, we can begin to engineer novel inhibitors specific to the multiple 
chaperone-buffering systems present within cancer cells in order to ameliorate 
or irradicate this condition.  
 54 
CHAPTER TWO:  EXPRESSION OF A NOVEL RNA APTAMER THAT 
DISRUPTS HSF1 ACTIVITY IN DROSOPHILA AND HUMAN CANCER 
CELLS. 
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2.1  INTRODUCTION: 
 Heat shock factor (HSF) is a transcription factor that responds to a 
variety of signals to regulate the expression of a broad spectrum of target 
genes (Biggs, Zavitz, et al, 1994; Xiao, Zuo, et al, 1999).  As mentioned 
previously in Chapter 1, Drosophila and S. cerevisiae each contain a single 
HSF1 gene, while in mammals and plants multiple isoforms exist that appear 
to have specialized functions  (Czarnecka-Verner, Yuan, et al, 2000; 
Rabindran, Giorgi, et al, 1991; Sarge, Zimarino, et al, 1991; Schuetz, Gallo, et 
al, 1991) and is responsible for activating the heat shock response, a 
mechanism that is highly conserved among different kingdoms (Lindquist, and 
Craig, 1988a).  During this response, HSF1 activates the expression of a 
specific set of heat shock genes, resulting in the accumulation of molecular 
chaperones that allow the organism to cope with cellular damage induced by 
the thermal stress.  Among organisms that contain a single HSF1 gene, its 
activity is required at specific stages in the orgnaism’ life cycle  (Wiederrecht, 
Seto, and Parker, 1988, Jedlicka, Mortin, and Wu, 1997; Walker, Thompson, 
et al, 2003; Morley, and Morimoto, 2004).  However, higher organisms like 
mammals have evolved multiple HSF's that have specialized functions during 
animal developement (Rabindran, Giorgi, et al, 1991; Sarge, Zimarino, et al, 
1991; Schuetz, Gallo, et al, 1991; Xiao, Zuo, et al, 1999).  Thus, HSF appears 
to have evolved multiple important regulatory roles in mammalian cells that 
extend beyond its role in the heat shock/stress response.  
Although mammalian HSF1 activity is not required for animal viability, it 
does protect cells from various forms of stress (Murray, Whitfield, et al, 2004; 
Sarge, Zimarino, et al, 1991; Trinklein, Murray, et al, 2004) and also has been 
implicated in cancer as a “non-classical oncogene”.  HSF1 activity promotes 
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tumor formation and maintenance of the transformed cancer cell phenotype 
without affecting the viability of normal cells (Dai, Whitesell, et al, 2007).  
Therefore, HSF1 functions to promote cell survival even under conditions that 
could potentially become deleterious to the host, such as development of the 
transformed state. 
To further understand HSF1 function during animal development and its 
role in tumor maintenance, I utilized the RNA aptamer technology in a 
chemical-genetic approach to inhibit HSF1 activity in both Drosophila and 
human cancer cells.  In this chapter, I report the design, construction, and 
validation of a potent inhibitory aptamer RNA molecule for HSF1 called 
iaRNAHSF.  This iaRNAHSF contains two HSF1 binding domains engineered 
from a previously isolated RNA aptamer that targets the highly conserved 
HSF1 DNA binding domain-Linker region (Zhao, Shi, et al, 2006).  In 
Drosophila, I demonstrate that this iaRNAHSF can interfere with HSF1 trans-
activation function under both non-induced and heat shock conditions in vivo.  
Under non-stressed conditions, systemic iaRNAHSF expression results in 
decreased HSF1 occupancy at the Hsp83 (63B) genomic locus, resulting in a 
significant decrease of transcribed Hsp83 mRNAs. Additionally, Drosophila 
animals that express iaRNAHSF display morphological abnormalities that 
resemble known Hsp83 mutants at high frequencies, consistent with previous 
reports that implicate Hsp83 in animal trait variation (Rutherford, and 
Lindquist, 1998; Sollars, Lu, et al, 2003; Yeyati, Bancewicz, et al, 2007; Yue, 
Karr, et al, 1999).  I also demonstrate that during thermal stress iaRNAHSF 
expression compromises HSF1 activity, resulting in the attenuation of the heat 
shock response.  I also confirm the functional specificity of iaRNAHSF-HSF1 
interaction using a reciprocal suppression test in which the developmental 
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defects induced by iaRNAHSF or HSF1 over-expression are effectively 
attenuated by the co-expression of the constructs.  Lastly, because of the 
broad implication of increased levels of heat shock proteins in diseases such 
as human cancer (Dai, Whitesell, et al, 2007; Kang, Plescia, et al, 2007; Soti, 
Nagy, et al, 2005; Xiao, Pacyna-Gengelbach, et al, 2005; Zaarur, Gabai, et al, 
2006), I examined the effect of iaRNAHSF under conditions that model cellular 
transformation in flies and mammalian cancer cells.  In Drosophila, HSF1 
inhibition by iaRNAHSF suppresses the abnormal phenotypes that arise from 
expression of gain-of-function mutants of the Epidermal Growth Factor 
Receptor (EGFR) ellipse mutant, and Raf oncogenes within the wing and eye 
tissues, respectively.   
The phenotypic effects of iaRNAHSF expression are similar to Hsp83 
mutants to, or treatment of EGFREllipse and Raf mutant flies with the Hsp83 
inhibitor 17-allylamino-17-demethoxygeldanamycin  (17-AAG), a frequently 
used anticancer agent in humans (Sawai, Chandarlapaty, et al, 2008).  In 
human cancer cells, iaRNAHSF shows the properties of a potent anti-tumor 
drug with activities comparable to those of 17-AAG.  In particular, iaRNAHSF 
induces a cancer-specific apoptotic response that correlates with the depletion 
of Hsp70 and Hsp90 family members, essential components of a larger 
chaperone network thought to be required for the maintenance of the 
transformed phenotype associated with cancer.  Collectively, my results 
indicate that HSF1 inhibition by iaRNAHSF attenuates mitogenic growth 
signaling and inhibits transformed growth, thus making iaRNAHSF a promising 
new reagent worthy of further characterization in whole animal cancer studies.    
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2.2.  RESULTS 
2.2.1.  Design, construction, and validation of the iaRNAHSF expression 
system 
Previously, our group isolated and characterized an RNA aptamer 
(AptHSF-RA1) that recognizes the DNA binding-linker domain of the 
Drosophila HSF with an apparent dissociation constant (Kd) of 20-40nM (Zhao, 
Shi, et al, 2006).  Shi H. et al previously developed an efficient scheme to 
deliver RNA aptamers as synthetic genes in transgenic flies to test their in vivo 
effects (Shi, Hoffman, and Lis, 1999).  Here I have adapted this general 
delivery method to design and construct a genetic system for the expression of 
AptHSF-RA1.  
In particular, I have taken a minimized version of the aptamer and 
augmented it in two ways.  First, in order to effectively target the multi-domain 
HSF protein, I designed a divalent version by joining together two identical 
aptamers through two hinges and a three-way junction (Figure 2.1A).  
Analogous to the F(ab!)2 fragment of an antibody, this configuration 
dramatically increased the avidity of the resulting RNA molecule to HSF.  
Second, the molecule contains a self-cleaving hammerhead ribozyme that 
ligates the free ends of the cleaved RNA, resulting in increased RNA stability 
while at the same time making it possible to generate block polymers of the 
coding sequence so that a single synthetic polymeric template can code for 
multiple aptamer RNAs from every transcription cycle (Shi, Hoffman, and Lis, 
1999).  The resulting molecule, as shown in Figure 2.1A, is named inhibitory 
aptamer RNA HSF (iaRNAHSF).   
To determine the apparent affinity of our engineered dimeric construct 
to HSF1, I performed electrophoretic mobility shift assays (EMSA) using 
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excess purified dHSF protein and limiting amounts of in vitro- transcribed, 32P-
UTP-substituted iaRNAHSF (<1nM) (Figure 2.1B).  The results demonstrate that 
the designed dimeric construct improves the apparent affinity of the original 
monomeric HSF aptamer several fold, yielding an apparent Kd of ~8nM 
(Figures 2.1 B&C).  This improved avidity is sufficient to prevent HSF from 
binding to its natural promoter sequences, as seen from gel shift competition 
assays using limiting amounts of radiolabelled Hsp70 and Hsp83 promoter 
DNA (<1nM).  In these experiments, the addition of increasing amounts of cold 
iaRNAHSF inhibits the formation of an HSF/DNA promoter complex relative to 
the addition of a control yeast tRNA molecule (Figure 2.2A).  Under these 
conditions, inhibition of HSF binding to the Hsp83 promoter requires 
approximately 5-fold more iaRNAHSF than does the inhibition of HSF binding to 
Hsp70 promoter (Figure 2.2B).  These differences are likely a consequence of 
the spacing and arrangement of the HSF binding sites between the Hsp83 and 
Hsp70 promoters (Fernandes, Xiao, and Lis, 1994; Fernandes, Xiao, and Lis, 
1995).   
To determine if iaRNAHSF inhibits HSF1 transcriptional activity in the 
complex milieu of a whole cell extract, I added increasing amounts of non-
radiolabelled iaRNAHSF to yeast whole cell extracts expressing HSF1 and 
incubated the reaction in an in vitro G-less cassette transcription template that 
contains HSF1 binding sites, heat shock elements (HSE) within the promoter 
(Figure 2.3).  In this system, one can directly measure the inhibitory potential 
of an aptamer in whole cell extracts because transcription of the reporter 
occurs when ATP, CTP and UTP is added to the reaction.  To visualize the 
final transcript, a small amount of radiolabelled UTP was added. 
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Figure 2.1:  iaRNAHSF binds to HSF avidly, Kd=8nM.  
A). Lowest energy diagram predicting the secondary structure of the aptamer 
RNA using M-fold. iaRNAHSF DNA sequence (green letters correspond to the 
hammerhead ribozyme and red letters corresponds to the HSF aptamer 
sequence).  B).  Electrophoretic motility shift assay (EMSA) using radiolabelled 
iaRNAHSF (1nM) and increasing amounts of dHSF protein shows that the 
aptamer RNA binds to its target avidly.  C). Quantification of independent 
EMSA assays reveals the apparent affinity of the iaRNAHSF Kd=8 nM (n=5, 
error indicates %SEM) (Figure is displayed on multiple pages) 
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Figure 2.2:  iaRNAHSF competes with HSF DNA binding at native 
promoters in vitro.  
A). HSF EMSA using limiting amounts of Hsp83 promoter DNA (1nM)(-
449>+114) (lanes 2-12), and increasing molar (M) concentrations of cold “non-
radiolabelled” iaRNAHSF (lanes 9-12) or yeast tRNA (lanes 5-8).  B).  
Quantification of competition experiments by filter binding assays using Hsp83 
(-449>+114) or Hsp70 (-200>+64) promoter DNA.  Data normalized to highest 
yeast tRNA signal (Hsp70 %SEM n=3, Hsp83 %SEM n=6). 
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Figure 2.3:  iaRNAHSF inhibits HSF1 induced transcription in vitro.  
Addition of non-radiolabelled iaRNAHSF to yeast whole cell extracts inhibits 
HSF1 ability to induce transcription from a G-less cassette that contains heat 
shock regulatory elements (HSE) upstream the start site.  Effective 
transcription inhibition is first observed at ~10nM iaRNAHSF. 
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The results show that iaRNAHSF significantly compromises HSF1 
transcriptional activity even at the lowest aptamer concentration (10nM). 
In Drosophila, as in most eukaryotes, the amount of gene product 
generally depends on gene dosage; therefore, more copies of iaRNA coding 
sequence introduced into an animal or cell results in higher iaRNA levels.  To 
increase iaRNA production and accumulation in animals, I developed a new 
cloning strategy that systematically generates repetitive head-to-tail iaRNA 
coding genes that double in size during every cloning cycle (Figure 2.4). This 
expression system allows for high-level expression of aptamer RNAs because 
each repeating aptamer gene within a given polymeric template is flanked by a 
self-cleaving hammerhead ribozyme (Figure 2.5A).  Upon transcription of the 
polymeric template RNA, the hammerhead ribozyme undergoes self-cleavage, 
resulting in the release of multiple free functional iaRNA's from every 
transcription cycle (Shi, Hoffman, and Lis, 1999).  This self-cleavage insures 
that the aptamer RNAs are not polyadenylated for export and remain localized 
within the nucleus.  In addition, the hammerhead ribozyme undergoes a self-
ligation reaction that produces covalently closed circles that protect RNA 
molecules from degradation (Shi, Hoffman, and Lis, 1999).  To determine 
whether our engineered construct does in fact undergo self-cleavage when 
transcribed from a polymeric DNA template, I performed time dependent in 
vitro transcription reactions using radiolabelled 32P-UTP as substrate.  In these 
experiments, the hammerhead ribozyme undergoes self-cleavage as observed 
by the appearance and accumulation of the mature iaRNAHSF (200 basepairs) 
from a nascent transcript (487 bases) within the first few minutes of the 
reaction (Figure 2.5B).  Because the fully processed form of the aptamer 
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Figure 2.4:  Polymerization of iaRNAHSF genes results in the synthesis of 
multiple aptamers from each round of transcription.  Strategy for the 
polymerization of the iaRNAHSF gene: Gateway# cloning sequences, AttB1 and 
AttB2, flank the iaRNA
HSF gene that contains two HSF aptamers upstream of a 
hammerhead ribozyme, a Xho1 (5!) site, and a Sal1 (3!) site. Each Gateway# 
ready unit is digested with Xho1 or Sal1 and the resulting digests are ligated 
together, creating a polymer of 2 iaRNAHSF genes.  Only fragment #3 results in 
the proper head to tail orientation of the polymeric gene and the appropriate 
Gateway# flanking sequences.  Using the polymer of 2 as a template and 
repeating the dimerization strategy creates a polymer of 4.  Overall, geometric 
progression of polymeric length is achieved in each subsequent round of 
dimerization. 
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Figure 2.5:  Design of iaRNAHSF expression system in vivo.  
A).  Diagram of a polymeric template of 16 iaRNAHSF gene units and their 
corresponding transcripts (i) corresponds to the first processed iaRNAHSF 
which lacks a hammerhead, (ii) corresponds to subsequent iaRNAHSF that 
contain the “self-cleaving” hammer head ribozymes, and (iii) corresponds to  
the final processed hammer head ribozyme that does not bind to HSF).  B).  In 
vitro transcription of a polymer of 2 iaRNAHSF repeats demonstrates the 
effective release and accumulation of iaRNAHSF (200 bases), from its full 
length transcript (487 bases).  Transcription reactions were performed using 
T7 Polymerase and radiolabelled 32P-UTP.   C).  Determination of iaRNAHSF 
stability in Drosophila S2 cell shows that  iaRNAHSF has an apparent half-life 
(t1/2)~2hrs.  iaRNA
HSF levels are plotted as a function of time after inhibition of 
Pol II transcription with !-amanitin (values normalized to 18S rRNA and 
quantified by RT-qPCR, n=3).  D).  Quantification of iaRNAHSF levels relative to 
18S rRNA among animals that express iaRNAHSF (white bar) or parental 
controls that contain the iaRNAHSF genes but lack Gal4 protein (black) (%SEM 
n=3). 
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 appears prior to the full-length transcript, self-cleavage occurs before the T7 
polymerase can reach the end of the aptamer array. 
To test the stability of iaRNAHSF in living cells, I generated stable 
Drosophila S2 cells that contain 8 tandem iaRNAHSF coding sequences 
downstream from the inducible metallothienin promoter.  I induced the 
production of iaRNAHSF with 0.5mM copper sulfate for 24hrs, blocked further 
transcription with alpha-amanitin, and analyzed the rate of iaRNAHSF decay by 
quantifying the levels of iaRNA relative to 18S ribosomal RNA at specific times 
using reverse transcription quantitative PCR (RT-qPCR).  These experiments 
show that the in vivo half-life of iaRNAHSF is 2 hours, which compared to the 
turn over rate of most endogenous RNAs (minutes), is a dramatic 
improvement in overall RNA stability (Figure 2.5C).  
To generate Drosophila stocks that express iaRNAHSF in specific tissues 
or developmental stages, I created transgenic fly lines that contain 8 and 16 
repeating iaRNAHSF units downstream from the inducible Gal4/UAS promoter 
(Brand, and Perrimon, 1993) using P-element transformation vectors.  High 
level iaRNAHSF was achieved by recombining multiple aptamer genes on a 
single chromosome.  To preserve this high-level iaRNAHSF construct, a 
Drosophila  line expressing ~50 aptamer genes was produced from individual 
genomic insertions containing 8 and 16 repeating iaRNAHSF genes.  By 
expressing Gal4 protein using the tubulin promoter in this genetic background, 
iaRNAHSF can be induced in whole animals to approximately 3 times the molar 
concentration of 18S rRNA, or ~150 fold higher than parental strains that lack 
Gal4 (Figure 2.5D).  Therefore, this expression system is highly effective for 
achieving high iaRNAHSF expression in Drosophila.  
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2.2.2.  Efficacy of iaRNAHSF as a HSF antagonist 
To determine the in vivo efficacy of iaRNAHSF as a HSF1 antagonist, I 
measured its effect on known HSF gene targets under both non-heat shock 
and heat shock conditions.  I focused my attention on the Hsp83 gene (63B 
locus) based on the fact that under non-stress inducing conditions HSF is 
significantly enriched at this locus relative to any other chromosomal site 
(Westwood, Clos, and Wu, 1991; Yao, Munson, et al, 2006).  I investigated the 
effects of iaRNAHSF expression at three different levels: HSF binding to the 
Hsp83 chromosomal locus, inhibition of Hsp83 mRNA levels, and whole 
Drosophila  phenotypes.  Immunofluorescent antibody staining for HSF on 
Drosophila salivary gland chromosomes confirms that under normal growth 
conditions HSF preferentially binds to the Hsp83 locus (63B) (Figure 2.6A, 
compare HSF signal (red) relative to GAF control (green)).  However, upon 
iaRNAHSF expression, the HSF levels at the 63B locus is effectively reduced by 
approximately 50% (p=0.035) (Figure 2.6B-C).  
Previous reports have implicated the enhancer elements and upstream 
regulatory sequences present in the promoter regions of the Hsp83 gene as 
being critical for expression  (Xiao, and Lis, 1989).  Because no direct 
evidence has yet been reported to determine HSF!s role in the constitutive 
expression of Hsp83, I decided to test whether HSF inhibition compromises 
Hsp83 expression by quantifying the levels of Hsp83 mRNA in iaRNAHSF-
expressing and wild type (Gal4 parental) Drosophila animals. Here, animals 
that express iaRNAHSF have ~50% less Hsp83 mRNAs compared to control 
animals (p=0.008) (Figure 2.6D), thus indicating that under non-heat-shock 
conditions HSF activity is required for the expression of Hsp83.  I confirmed 
this result using another approach that involved depleting HSF from  
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Figure 2.6:  Constitutive iaRNAHSF expression inhibits HSF activity at 
Hsp83 (63B locus) under NHS conditions.  
A).  HSF distribution within WT Drosophila chromosomes shows it is most 
abundant at Hsp83 gene (63B locus) under non-induced conditions (NHS).  
Antibodies: Red=HSF, Green=GAF (control).  B). Constitutive iaRNAHSF 
expression results in decreased HSF binding to Hsp83 gene (63B locus) 
during NHS conditions. C).  Quantification of the relative intensities shown in 
panel B in WT (n=29) and iaRNAHSF expressing animals (n=29). (Observed 
signals normalized to GAF intensities at 63A).  D).  Constitutive iaRNAHSF 
expression results in decreased Hsp83 mRNAs under NHS conditions.  
(Quantification of Hsp83 mRNAs in WT and iaRNAHSF expressing animals 
using RT-qPCR.  WT n=6, iaRNAHSF n=6).  E).  HSF RNAi depletion within 
Drosophila S2 cells results in decreased Hsp83 mRNAs similar to the 
iaRNAHSF effects observed in panel D (mRNAs quantified by RT-qPCR.  Error 
%SEM,  LacZ RNAi “WT” n=4, HSF RNAi n=4). 
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Drosophila S2 cells using RNAi.  In these experiments, HSF knockdown 
resembled the effects of iaRNAHSF expression and reduced Hsp83 transcript 
levels by 50% (p=0.017) (Figure 2.6E, compare HSF RNAi versus LacZ RNAi 
treatment), thus further demonstrating that normal HSF activity is required for 
the expression of Hsp83 mRNA under normal growth conditions.   
Adult Drosophila that constitutively express iaRNAHSF display abnormal 
abdominal segments, wing shape and morphology, bristles, and eye 
protrusions in specific genetic backgrounds at high frequencies (Figure 2.7A).  
Intriguingly, these aptamer-induced phenotypes closely resemble the 
abnormalities that occur when Hsp83 activity is reduced, although at much 
greater frequencies than the abnormal traits observed among Hsp83  
hypomorph mutants, Hsp83e6D (Rutherford, and Lindquist, 1998; Sollars, Lu, et 
al, 2003).  This increased penetrance is best illustrated by analyzing the 
notched wing phenotype, which occurs in approximately ~90% of iaRNAHSF 
expressing animals, but only present at ~5-20% in wild-type animals that have 
been raised in media containing the Hsp83 inhibitor 17AAG during the first two 
generations after exposure.  Surprisingly, less than 1% of Hsp83e6D mutants 
display this notched wing abnormality.  Taken together, these results show 
that under non-heat shock conditions, iaRNAHSF expression compromises HSF 
ability to bind DNA, such as the Hsp83 locus, and that this decrease in HSF 
occupancy results in decreased Hsp83 transcript levels and mimicry of certain 
Hsp83 mutant phenotypes. 
Under heat shock conditions, HSF becomes rapidly activated, resulting 
in the robust expression of heat shock genes (Saunders, Core, and Lis, 2006).  
However, high-level iaRNAHSFX48 expression compromises HSF binding to the 
major Hsp70 loci (87A and 87C) after exposure to heat stress (Figure 2.7B,  
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Figure 2.7:  Systemic iaRNAHSF expression inhibits HSF activity in vivo.  
A). HSF inhibition by iaRNAHSF results in adult animals that display abnormal 
animal morphology within abdominal segments, wings, thorax and eye 
structures at high frequencies (n>500 animals).  B).  High-level iaRNAHSF 
inhibits HSF binding to Hsp70 genes under HS conditions.  (Left column=WT, 
Right column=iaRNAHSFX48.  Antibodies: Red=HSF, Green= GAF.  Blue=DNA.  
Dot=87A locus, Triangle=87C locus).  C).  Quantification of the relative 
fluorescence of HSF in panel E at Hsp70 (87AC loci) among WT or 
iaRNAHSFX48 expressing animals (Signals normalized to GAF intensity at 86E 
locus.  WT n=5; iaRNAHSF n=14). D).  Constitutive iaRNAHSF expressing 
compromises major heat shock gene activation by HSF during heat stress 
(mRNAs quantified by RT-qPCR.  Error % SEM, WT n=4, iaRNAHSF n=4) 
(Figure is displayed on multiple pages) 
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left column=WT, right column=iaRNAHSF expressing animals).  Quantification 
of the HSF antibody signals normalized to GAGA factor antibody staining at a 
nearby site that does not undergo “puffing” (86E) shows the strong level of 
iaRNAHSF inhibition of the ability of HSF to bind at both the 87A and 87C loci 
(Figure 2.7C).  Furthermore, quantification of the total RNA from three major 
classes of heat shock gene, Hsp26, Hsp70 and Hsp83, demonstrates that 
iaRNAHSF expression compromises overall HSF activity and thus attenuates 
the normal heat shock response (Figure 2.7D).  Figures 2.6 and 2.7 
demonstrate that iaRNAHSF expression results in decreased HSF activity under 
both normal and heat-shock conditions in vivo. 
 
2.2.3.  Functional specificity of the in vivo iaRNAHSF-HSF interaction  
 Our engineered molecule, iaRNAHSF, shows several properties of a 
highly specific drug, including its high affinity for HSF (5-10 nM in vitro) and its 
ability to inhibit HSF binding to target genes as well as the expression of heat 
shock genes in vivo.  To more rigorously prove the specificity of the iaRNAHSF 
molecule to HSF, I made use of the fact that over-expression of either 
iaRNAHSF or HSF results in increased lethality during the pupae stage.  I 
reasoned that this lethality could be ameliorated by overexpressing the 
complementary interacting partner within the same organism.  This genetic 
approach is analogous to factor titration or add-back in vitro binding assays, 
where the effects of an RNA aptamer are reversed by the addition of excess 
target protein (Sevilimedu, Shi, and Lis, 2008; Shi, Hoffman, and Lis, 1999; 
Zhao, Shi, et al, 2006).        
In the first scenario, I asked if HSF over-expression could suppress the 
abnormalities induced by iaRNAHSF over-expression.  Here, systemic 
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iaRNAHSF expression results in lethality that occurs with increasing iaRNAHSF 
gene dosage (Figure 2.8A compare animals that express 8, 24 and 48 
iaRNAHSF genes), a finding that could potentially be attributed to the fact that 
HSF is an essential gene in Drosophila (Jedlicka, Mortin, and Wu, 1997).  This 
iaRNAHSF-induced effect is effectively suppressed upon HSF coexpression 
(Figure 2.8B, compare gray and blue column).  Additionally, I took advantage 
of Drosophila genetics to ask if the abnormal notching wing defect that occurs 
at high frequency in iaRNAHSF expressing animals could be suppressed by co-
expression of a non-iaRNAHSF binding protein such as GFP.  Figure 2.8C 
shows that the notched wing defect only occurs in iaRNAHSF-expressing 
animals and is absent in any of the parental stocks (compare parental controls 
i-ii versus iii).   This abnormality is not altered upon GFP over-expression but 
is effectively rescued upon overexpression of either HSF, or Hsp83, a major 
product of HSF activity in non-stressed cells (Figure 2.8C, compare iv versus v 
& vi respectively).   
I also assayed if iaRNAHSF over-expression could ameliorate the 
abnormalities induced by HSF over-expression through the use of a 
complementarity test.  Here, I find that tissue-specific HSF over-expression 
results in abnormally small salivary glands in Drosophila (Figure 2.8B, 
compare right and left panel), and that this abnormality is suppressed when 
HSF is coexpressed with iaRNAHSF (Figure 2.8D, middle panel).  Comparison 
of the salivary gland length between Drosophila and strains that over-express 
HSF or animals that over-express HSF and iaRNAHSF shows that iaRNAHSF 
can inhibit HSF in vivo and restore the salivary gland morphology to near wild 
type size (Figure 2.8D).  Furthermore, I find that high-level systemic HSF over-
expression also results in a high frequency of lethality (Figure 2.8B) that is  
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Figure 2.8:  iaRNAHSF is specific to HSF in vivo.  A).  Aptamer expression 
induces lethality in a gene dosage dependent manner.  (WT is parental Gal4 
line; X8, X24, X48 corresponds to aptamer gene dosage under tubulin Gal4 
transcriptional control).  B).  Co-expression of iaRNAHSF and HSF suppress the 
lethality!s induced by either high-level iaRNAHSF or HSF over-expression  
(Error= number of surviving adults over 200 Drosophila larvae).  C).  HSF and 
Hsp83 over-expression, but not GFP over-expression suppresses the notched 
wing phenotype induced by high-level iaRNAHSF expression (I & II are WT 
parental controls: UAS.iaRNAHSF & Tubulin Gal4 stocks).  (III) iaRNAHSF 
expressing animals with notched wings (UAS.iaRNAHSF + Tubulin Gal4).  (IV) 
iaRNAHSF expressing animals that over-express GFP protein 
(UAS.GFP+UAS.iaRNAHSF+TubGal4).  (V) iaRNAHSF expressing animals with 
an additional copy of Hsp83 gene (UAS.iaRNAHSF + Tubulin Gal4 + duplication 
61F-64B); and (VI) corresponds to animals that over-express iaRNAHSF and 
HSF protein (UAS.iaRNA+Tubulin Gal4+UAS.HSF).   D).  iaRNAHSF 
suppresses the adverse effects of HSF over-expression in the Drosophila 
salivary glands (Left=over-express HSFGFP; Middle= over-express 
HSFGFP+iaRNA; Right=WT.  Salivary gland Gal4 driver 6983, p{GawB}c729).  
E).  Quantification of salivary gland length of panel C (Error % SEM, WT n=9; 
HSFGFP n=8; HSFGFP+iaRNAHSF n=15) (Figure is displayed on multiple pages). 
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Figure 2.8:  (Continued)
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Figure 2.8 (Continued) 
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effectively suppressed by iaRNAHSF co-expression, resulting in viable and 
fertile animals (Figure 2.8B).  Taken together, I conclude that the iaRNAHSF 
does not produce its phenotypes by binding to random proteins, but rather 
acts on the intended target, HSF, by inhibiting expression of HSF!s primary 
target, Hsp83, under non-inducing conditions.  
 
2.2.4 iaRNAHSF expression attenuates phenotypes of hyperactive 
mutations in the Drosophila MAPK signaling pathway 
As mentioned previously in chapter 1, Hsp83 (Hsp90 in mammals) is 
known to modulate the MAPK signaling pathway, a well conserved and 
important regulatory pathway that is commonly overactivated in human tumors 
(Jones, Zhang, et al, 2008; Parsons, Jones, et al, 2008; Pratt, and Toft, 2003). 
In Drosophila, gain-of-function mutations within the MAPK pathway do not 
result in tumor formation; rather, hyperactivation of the MAPK pathway results 
in altered cell fate specification and abnormal tissue morphology.  
Components of this pathway, such as the epidermal growth factor receptor 
(EGFR) and Raf oncogenes, depend on normal levels of Hsp83 activity (Biggs, 
Zavitz, et al, 1994; Citri, Gan, et al, 2004; Neckers, 2002; Sawai, 
Chandarlapaty, et al, 2008; Van der Straten, Rommel, et al, 1997).  In these 
cases, Hsp83 is required for maintaining these signaling proteins in a properly 
folded state as well as localizing and regulating their kinase activity.  This 
dependency by MAPK components on Hsp83 activity encouraged me to 
investigate the inhibitory potential of the HSF aptamer in vivo using Drosophila 
gain-of-function EGFRElp or RafBT98 mutants given my previous work where I 
found that HSF inhibition reduces the total levels of Hsp83 protein.   
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First, I asked whether iaRNAHSF expression could effectively suppress 
the abnormalities induced by gain-of-function mutations of the Drosophila 
EGFRElp and RafBT98 oncogenes.  In the former case, heterozygous flies that 
express EGFRElp have been previously shown to contain abnormal wing vein 
morphology (Li, and Li, 2003) (Figure 2.9A).  This abnormality is effectively 
suppressed when HSF is inhibited by iaRNAHSF, when Hsp83 activity is 
compromised by the expression of the Hsp83e6D antimorphic mutant, or when 
hemizygous EGFRElp flies are treated with 17-AAG (Figure 2.9A). Similarly, 
heterozygote animals that express gain-of-function RafBT98 have been shown 
to contain multiple R7 cells within each ommatidium, resulting in flies with a 
rough eye morphology (Van der Straten, Rommel, et al, 1997) (Figure 2.9B) 
that has been shown to be dependent of Hsp83 activity (Van der Straten, 
Rommel, et al, 1997).  Here, I show that this phenotype is also effectively 
suppressed by iaRNAHSF expression, by reducing Hsp83 activity by the 
expression of the Hsp83e6D antimorphic mutant, or treatment of RafBT98 
animals with 17-AAG (Figure 2.9B).  Approximation of the affected surface 
area of the eye in each of these genetic backgrounds shows that overactive 
MAPK signaling phenotypes causes a rough eye phenotype and this 
abnormality can be effectively attenuated by iaRNAHSF expression or Hsp83 
inhibition (Figure 2.9C).  This reversal of the tumor-related phenotypes in 
Drosophila caused by known oncogenes encouraged me to extend my 
analysis of the HSF aptamer!s potential anti-tumor properties to mammalian 
cells. 
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Figure 2.9:  Expression of iaRNAHSF suppresses gain-of-function 
mutations of genes in the MAPK signaling pathway.  A).  iaRNAHSF 
expression and Hsp83 inhibition suppress the abnormal wing phenotype 
induced by the EGFrElp mutant.  B). iaRNAHSF expression and Hsp83 inhibition 
suppress the rough eye phenotype induced by activated RafBT98 mutant. C).  
Quantification of rough eye phenotypes in panel B calculated by area.  Error % 
SEM, WT (n=5); RafBT98 (n=26); RafBT98 + iaRNAHSF (n=33); RafBT98 + 
Hsp83e6D (n=33); RafBT98 + 3.6uM 17AAG (n=33). 
 
 90 
 
 
 91 
2.2.5.  iaRNAHSF expression induces apoptosis in human cancer cells 
To investigate the effects of iaRNAHSF in human cancer cells, I 
expressed the aptamer in cervical carcinoma (HeLa), and chemically 
transformed kidney cells (293T) and determined its effects within the first 5 
days of expression by culturing the cells using the selectable marker 
blasticidin, which is encoded within the vector containing the aptamer.  Non-
transfected cells were killed within the first day using a predetermined amount 
of blasticidin, and only those cells that were resistant to blasticidin treatment 
were used throughout the rest of the experiments.  Among transfected cells, 
iaRNAHSF expression dramatically altered the morphology of cells causing 
them to round up and detach from the culture plate.  Interestingly, iaRNAHSF 
expression did not have significant effects on the morphology of primary non-
transformed human cells (IMR90) (Figure 2.10A).  To ensure that both the 
primary (IMR90) and cancerous cells express aptamer RNA to a similar 
extent, I performed quantitative real-time PCR (qPCR) and found that the 
relative aptamer levels were approximately equal for both control and the HSF 
aptamer RNA in both cell lines (Figure 2.10B).  Because detached cells often 
correlate with increased cell death, I performed apoptotic assays in 
collaboration with Marc Antonyak in Rick Cerione!s laboratory.  Together, we 
stained cells with DAPI and quantified the number of apoptotic cells in parental 
cells that either lacked, or expressed the HSF aptamer or a control RNA (Rev) 
using nuclear fragmentation as a read-out of apoptosis (Figure 2.10C).  We 
found that iaRNAHSF expression did not result in a significant amount of cell 
death in the normal IMR90 cells.  In contrast, iaRNAHSF expression induced an 
approximately 9-fold increase in cell death among HeLa cells (63% of the 
population, p=0.0001), and approximately a 7-fold increase in apoptosis in  
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Figure 2.10:  iaRNAHSF induces a cancer cell specific apoptotic response.   
A). iaRNAHSF expression induces a morphological defect among transformed 
human cervical carcinoma (HeLa) and chemically transformed human kidney 
cells (293T); but not in a primary human lung fibroblast cell line (IMR90) after 
96 hours post transfection.  B).  Control RNA and aptamer RNA (iaRNAHSF) 
are expressed to near equal levels in semi-stable HeLa & IMR90 cells after 
24hrs of RNA expression (RNA values normalized to GAPDH, n=3).  C).  
Expression of iaRNAHSF induces apoptosis in HeLa and 293T cells 
approximately ~10-fold (p<0.0001), and ~7-fold (p<0.0001) respectively 
(apoptosis was determined by quantifying the number of cells undergoing 
nuclear fragmentation scored by DNA staining at 96hrs post RNA expression, 
all values n>8) (Figure is displayed on multiple pages).  
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Figure 2.10 (Continued)
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293T cells (40% of the population, p=0.0018) relative to cancer cells 
expressing a control RNA.  Collectively, our results indicate that HSF1 
inhibition results in a cancer cell-specific apoptotic response. 
Results in Drosophila revealed an HSF-Hsp90 regulatory interaction 
wherein HSF inhibition results in reduced Hsp90 expression, and the 
presentation of Hsp90 mutant-like phenotypes.  By contrast, Hsp90 over-
expression attenuates the abnormalities induced by high-level expression the 
HSF aptamer.  To explore whether this relationship also extends to cancer cell 
survival, I examined whether over-expression of Hsp90 suppresses the 
apoptotic response induced by iaRNAHSF expression in HeLa cells (Figure 
2.11A).  Indeed, I found that Hsp90, Hsp70 or HSF1 over-expression all 
effectively suppress the apoptotic response, indicating that HSF1 inhibition 
compromises the activity of the Hsp90/Hsp70 multi-chaperone complex 
(Figure 2.11B). 
Because approximately ~30% of iaRNAHSF-treated HeLa cells do not 
undergo apoptosis in our time restricted assays, I sought to analyze the 
prolonged effects of iaRNAHSF expression using anchorage-independent soft 
agar growth assays as an in vitro measurement of tumorigenecity.  As 
expected, HeLa cells expressing the Rev control RNA sequence grew in the 
soft agar matrix and formed large colonies to the same extent as non-
transfected control cells (Figure 2.12); however, HeLa cells expressing 
iaRNAHSF do not.  This shows that those cells that express iaRNAHSF yet have 
not undergone apoptosis (Figure 2.10C) exhibit a compromised transformation 
capacity that results in reduced growth on soft agar. 
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Figure 2.11:  Suppression of iaRNAHSF induced apoptosis by over-
expression of molecular chaperones.  A).  Over-expression of HSF1 or 
Hsp90, but not LacZ rescues the apoptotic response induced by iaRNAHSF 
over-expression.  B).  Quantification of results in panel A shows that over-
expression of molecular chaperones (HSF1 p<0.006, Hsp90 p<0.005, or 
Hsp70 p<0.002), but not random proteins (GFP or LacZ) can effectively rescue 
the aptamer induced apoptotic response (apoptosis was determined by 
quantifying the number of cells undergoing nuclear fragmentation scored by 
DNA staining at 96hrs post RNA expression, all values n>8).  
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Having established that Hsp90 over-expression rescues the aptamer effects 
within cervical carcinoma cells (Figure 2.11), and that treatment of HeLa cells 
with Hsp90 inhibitors compromises cancer cell viability (Bisht, Bradbury, et al, 
2003), I decided to compare the inhibitory effects of iaRNAHSF expression with 
17-AAG treatment using colony formation as a readout.  In this experiment, 
iaRNAHSF expression induces a similar cytotoxic response in HeLa  cells 
relative to the treatment of this cell type to 150nM 17-AAG (Figure 2.12, right 
panels).  Overall, HSF1 inhibition by iaRNAHSF closely resembles the effects 
observed upon Hsp90 inhibition in both Drosophila and human cancer models 
(Figures 2.9- 2.12).  
 
2.2.6.  HSF regulates cancer cell survival by compromising the activity of 
members of a chaperone !buffering" network 
To further explore the role of HSF1 inhibition and the resulting reduction 
in Hsp90 activity in human cancer cells, I examined the effects of iaRNAHSF on 
the MAP kinase pathway, which is known to be dependent on Hsp90 activity 
(Figure 2.9) (Bisht, Bradbury, et al, 2003; Pratt, and Toft, 2003; Cancer 
Genome Atlas Research Network, 2008).  I used EGF to activate this pathway 
in parental HeLa cells as well as HeLa cells expressing aptamer or control 
RNA (Figure 2.13).  By measuring the effects of EGF stimulation under 
conditions prior to the onset of apoptosis, I investigated the primary role of 
HSF1 inhibition on this specific cell-survival pathway without the complication 
of proteolysis induced by the apoptotic response.  In these experiments, 
MAPK pathway activation was measured using the Erk-p T202/Y204 antibody 
that recognizes the activated form of Erk1/2.  Here, I find that parental or 
control RNA expressing HeLa cells contain high levels of total Erk1/2 protein  
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Figure 2.12:  HSF1 inhibition by iaRNAHSF inhibits transformed growth in 
soft agar.  Soft agar analysis of non-transfected HeLa cells (top left), control 
RNA over-expressing HeLa (bottom left), shows that iaRNAHSF over-
expression (bottom right) inhibits cellular transformation (colony formation) in a 
similar manner as treatment of HeLa cells with 150nM 17-AAG (top right), a 
potent anti-cancerous pharmacological agent (pictures taken during Day 14). 
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that becomes activated upon EGF treatment (Erk-p) (Figure 2.13A).   In 
contrast, HSF1 inhibition by the aptamer results in a >75% decrease in total 
Erk1/2 levels, and this decreased level of Erk1/2 protein results in a 
corresponding decrease in the activated form of the protein (Figure 2.13A).  
Furthermore, I measured the levels of both total and phosphorylated Erk1/2 
protein in aptamer expressing cells that either over-express Hsp90 or its co-
chaperone Hsp70 partner, since the latter protein has also been shown to 
work in conjunction with Hsp90 in a multi-protein chaperone complex required 
by cancer cells for survival (Bagatell, and Whitesell, 2004; Workman, 2004; 
Powers, Clarke, and Workman, 2008;).  Here, over-expression of either Hsp90 
or Hsp70 rescues the loss of Erk1/2 protein, resulting in normal MAPK 
signaling activity.  This observation suggests that the attenuation of the MAPK 
signaling pathway that occurs upon HSF1 inhibition is due, at least in part, to 
downregulation of Hsp90 activity.  Using an antibody that recognizes the 
activated form of the EGF receptor (EGFR-p Y1068) I determined that 
aptamer-expressing HeLa cells contained decreased levels of activated forms 
of the EGF receptor after ligand treatment and that this effect was restored by 
the over-expression of Hsp70 or Hsp90 protein (Figure 2.13B).  I next 
considered whether the effects of HSF1 inhibition on cancer cells is due solely 
to the moderate depletion of Hsp90 levels, or whether apoptosis was triggered 
by the concerted depletion of other molecular chaperones.  Strikingly, I found 
that HSF1 inhibition by iaRNAHSF resulted in a severe reduction of Hsp70 
levels (Figure 2.14).  This finding suggests that the anti-cancerous properties 
of the aptamer are due in part to the restoration of pro-apoptotic signaling 
events, since Hsp70 directly inhibits the recruitment of pro-caspase 9 to the 
apoptosome (Beere, Wolf, et al, 2000; Jaattela, Wissing, et al, 1998; Steel,  
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Figure 2.13:  HSF1 inhibition by iaRNAHSF compromises MAPK signaling 
in human cancer cells.  A).  iaRNAHSF expression decreases the total levels 
of Erk protein resulting in a  similar decrease in the levels of Erk 
phosphorylation upon activation of MAPK by EGF addition (MAPK activation 
was induced by conditioning HeLa cells in serum free media for 12hrs before 
the addition of 100ng/ml EGF for 10 min.  For more details see Chapter 4-
Methods).  Intriguingly, the aptamer induced Erk loss is effectively rescued 
when molecular chaperones (Hsp90 & Hsp70) are over-expressed.  B).  
Similarly, iaRNAHSF inhibits EGFR activation (EGFR~p) upon MAPK activation 
by EGF ligand treatment (same conditions as panel A), and this effect is 
rescued by Hsp90 or Hsp70 over-expression.  (Triangles represent serial 
dilutions of parental (non-transfected) HeLa cells to be used for quantification 
purposes.  In these experiments, whole cell extracts were isolated from 
samples NOT undergoing apoptosis as determined by both cytological 
inspection before harvesting, and by the intact "non-cleaved! PARP antibody 
signal observed after immunoblotting.  Western blots contain ~40ug of total 
protein per sample electrophoresed on 10% SDS denaturing gels blocked with 
10% BSA instead of 5% milk).   
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Figure 2.14:  HSF1 inhibition by iaRNAHSF reduces levels of members of 
the !chaperone network".  Determination of the steady state levels of various 
molecular chaperones shows that HSF1 inhibition by iaRNAHSF results in a 
dramatic decrease among certain molecular chaperones in human cervical 
carcinomas cell compared with non-transfected parental cells, control RNA 
expressing (Rev), or cells that over-express iaRNAHSF& Hsp90.  Note that 
iaRNAHSF triggers an apoptotic response as shown by the cleaved PARP 
product*.  In these experiments Hsp60 was used as a loading control because 
its proteins levels did not seem to change throughout the course of the 
experiment. 
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Doherty, et al, 2004).  The anti-apoptotic functions of Hsp70 are emphasized 
by the fact that Hsp70 is expressed at high levels in many cancer types 
(Becker, Multhoff, et al, 2004; Nanbu, Konishi, et al, 1998) as well as by our 
findings that demonstrate that Hsp70 over-expression effectively attenuates 
the apoptotic response induced by the aptamer (Figure 2.14).  The above 
findings suggest that attenuating apoptosis by Hsp70 over-expression can 
also restore pro-survival signaling pathways (MAPK) in HeLa cells.  In any 
event, prolonged high-level aptamer expression clearly induces apoptosis as 
demonstrated by probing for the loss and cleavage of the well-documented 
caspase-3 downstream target, PARP (Figure 2.14). Under these same 
conditions, we notice that the levels of HSF1 and various other chaperones, 
including calnexin, PDI and Grp78 are depleted (Figure 2.14).  Hsp60, a 
mitochondrial specific chaperone, does not seem to be affected upon aptamer 
expression, suggesting that Hsp60 is either a highly stable protein or that its 
expression is independent of HSF1 transcriptional activity.   
To address the possibility that the loss of Hsp70, GRP78, and calnexin 
observed upon aptamer expression is not due to apoptosis-induced 
proteolysis, but rather by the inhibition of HSF1 transcriptional stimulatory 
activity, I determined the levels of these proteins under conditions where 
apoptosis was inhibited by Hsp90 co-expression (Figure 2.13 -2.14).  Under 
these conditions, I found that total HSF1 levels remain normal, indicating that 
the loss of HSF1 protein observed upon aptamer expression is not due to 
aptamer binding itself and causing degradation of the protein,  but rather due 
to apoptosis.  However, these cells still have reduced amounts of Hsp70 
(~50%), Grp78 (~25%), and calnexin (~50%) relative to (non-transfected) 
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HeLa cells, or RNA expressing control cells. This result indicates that these 
chaperones are HSF1 regulated genes.   
This simplest model to account for these findings is that the HSF 
aptamer acts by preventing HSF1 from binding to the heat shock elements on 
the promoters of the chaperone genes.  HSF1 is known to regulate the 
expression of many chaperones in mammals (Murray, Whitfield, et al, 2004; 
Trinklein, Murray, et al, 2004), some of which are therapeutic markers in the 
prognosis of diseases like cancer (Becker, Multhoff, et al, 2004; Nanbu, 
Konishi, et al, 1998).  I therefore decided to determine how iaRNAHSF 
expression affects highly agressive cancers that depend largely on normal 
Hsp90 activity and Hsp90 regulated signaling pathways (Pratt, and Toft, 
2003).  Here I found that the expression of iaRNAHSF significantly disrupts the 
cellular morphology of MDA-MB-231 highly aggressive breast cancer cells or 
BE(2)-M17 brain glioblastoma cells (Figure 2.15) in a similar manner as the 
expression seen in cervical carcinomas (Figure 2.10A).  This evidence 
supports the idea that the anti-cancerous properties of iaRNAHSF are due to 
the depletion of specific members of a larger chaperone network that is critical 
for maintenance of the cellular integrity of transformed cells.   
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Figure 2.15:  HSF1 inhibition by iaRNAHSF compromises survival of 
highly aggressive breast and brain cancers. iaRNAHSF expression induces 
a morphological defect among human breast cancer cells (MDA-MB-231) and 
human brain glioblastoma cells (BE(2)-M17).  In these experiments, each cell 
line was transfected with a mock vector, reverse aptamer sequence or the 
HSF1 aptamer and expressed using the EF1-a highly constitutive promoter.   
Semistable cell lines were analyzed after approximately 1 week post 
transfection and selection using the minimal amount of selection marker as 
determined by kill curve experiments (1ug/ml blasticidin). 
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2.3.  SUMMARY AND DISCUSSION 
2.3.1.  Stress response, molecular chaperones and tumorigenesis 
Cancer is a disease of genetic instability that promotes cellular 
adaptation to adverse microenvironments through specific mutations in 
proteins that promote deregulated cell growth (Hanahan, and Weinberg, 2000; 
Stoler, Chen, et al, 1999).  Because cancer cells generally exhibit increased 
proliferation rates compared to non-transformed cells, cancer cells require 
higher levels of nutrients, and therefore exhibit increased metabolic processes 
in poorly oxygenated, or hypoxic, microenvironments that result in highly- 
stressed growth conditions (Hahn, and Weinberg, 2002; Jolly, and Morimoto, 
2000). Therefore, in order for cancer cells to tolerate the higher levels of free 
radicals and the increased proteotoxicity generated by undergoing such 
adaptation, transformed cells generally increase the expression levels of  
molecular chaperones that can overcome the protein damage caused by this 
stressful environment.  Historically, the cytoprotective function of molecular 
chaperones was originally studied using thermotolerance as a model.  Here, 
animals containing elevated amounts of chaperones induced by a mild pre-
heat treatment can survive extreme stress conditions that are otherwise lethal 
in that particular organism (Sanchez, and Lindquist, 1990; Parsell, Sanchez, et 
al, 1991; Parsell, and Lindquist, 1993; Sanchez, Parsell, et al, 1993).   
Recently, strong evidence suggests that HSF1 activity is critical for 
cellular transformation and adaptation of cells to microenvironments that 
demand higher chaperone activity such as cancers (Dai, Whitesell, et al, 
2007).  In this regard, molecular chaperones that are regulated by HSF1 have 
been shown to stabilize the folding of mutated proteins such as dominant 
negative forms of the p53 tumor suppressor, various hormone regulated 
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receptors, and non-receptor tyrosine kinase (Blagosklonny, Toretsky, et al, 
1996; Cancer Genome Atlas Research Network, 2008).  Therefore, it is likely 
that many of the mutated proteins that promote carcinogenesis are stabilized 
by molecular chaperones (Blagosklonny, Toretsky, et al, 1996; Pinhasi-Kimhi, 
Michalovitz, et al, 1986; Luo, Solimini, et al, 2009).  The fact that cancer cells 
show increased levels of heat shock proteins (Hsps), in particular Hsp70 and 
Hsp90 (Becker, Multhoff, et al, 2004; Nanbu, Konishi, et al, 1998), together 
with the fact that the inhibition of these proteins sensitizes cancer cells to 
pharmacological treatment (Basso, Solit, et al, 2002; Bisht, Bradbury, et al, 
2003; Jaattela, Wissing, et al, 1998; Nanbu, Konishi, et al, 1998; Powers, 
Clarke, and Workman, 2008; Soti, Nagy, et al, 2005; Wei, Zhao, et al, 1994; 
Zaarur, Gabai, et al, 2006) strengthens this hypothesis and argues that during 
cellular transformation the activity of HSF1 is strongly up-regulated.   
 
2.3.2.  iaRNAHSF is a novel HSF inhibitor in vitro and in vivo 
Here I describe the in vivo utility of an aptamer that targets the highly 
conserved HSF DNA binding domain.  I engineered a potent HSF inhibitor 
using a dimeric molecule derived from a previously selected RNA aptamer 
(Kd~30nM), and demonstrate that making a single molecule containing two 
separate aptamers improves the affinity of the molecule approximately 3 fold, 
iaRNAHSF Kd~8nM.  Using a genetically controlled expression system, I 
demonstrate that I can express iaRNAHSF at high levels and inhibit HSF activity 
under normal and stress conditions in vivo.  Whenever a ligand such as an 
aptamer is used in vivo to study and manipulate the function of a protein, it is 
important to know whether the intended target is the only molecule recognized 
by the ligand or drug.  Here, I used a functional rather than binding assay to 
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demonstrate that iaRNAHSF!s binding is specific to HSF.  The abnormalities 
that arise from the expression of iaRNAHSF in Drosophila are effectively 
suppressed by HSF co-expression and not a control protein like GFP.  Since 
flies express a single HSF protein, this result suggests that the aptamer is 
exerting its effects by targeting its intended molecular surface (Zhao, Shi, et al, 
2006).  Conversely, the abnormalities observed in Drosophila induced by HSF 
over-expression are also effectively suppressed by iaRNAHSF over-expression, 
further supporting the specific nature of the aptamer-HSF interaction.  
In mammals, HSF1 inhibition is not essential for normal cell growth, but 
is critical for maintenance of the transformed cancer phenotype (Dai, 
Whitesell, et al, 2007). As a second test of specificity, I show that expression 
of iaRNAHSF severely compromises the viability of various cancer cells without 
compromising the viability of non-transformed human cells.  Together, the 
reciprocal suppression analysis of Drosophila phenotypes and cancer aptamer 
expression studies confirm the in-vitro specificity of the aptamer RNA to HSF 
(Zhao, Shi, et al, 2006). The fact that iaRNAHSF expression does not induce 
apoptosis in normal cells strongly suggests that cancer cells have distinct 
dependencies on the stress-sensitive chaperone network that are unique from 
its non-transformed counterpart.  
To date, only a small class of naturally occurring molecules have been 
identified that effectively inhibit chaperone function and sensitize cancer cells 
to pharmacological treatment (Wei, Zhao, et al, 1994; Westerheide, Kawahara, 
et al, 2006); however, little is known about the specific mechanism of 
inhibition.  For instance, the naturally occurring anthamycin compound 
geldanamycin and its derivates (17-AAG & DMAG) have been found to inhibit 
Hsp90!s function by blocking and inhibiting the Hsp90 ATPase domain 
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(Whitesell, Mimnaugh, et al, 1994).  Geldanamycin derivatives have recently 
shown great promise in the treatment of a wide variety of tumors.  In fact, 
these compounds are now in phase II clinical trials and have shown strong 
potential for the effective treatment of anaplastic cell lymphoma cell lines 
(Bonvini, Gastaldi, et al, 2002), acute myeloid leukemia (Minami, Kiyoi, et al, 
2002), chronic myelogenous leukemia (Gorre, Ellwood-Yen, et al, 2002), 
prostate cancer (Vanaja, Mitchell, et al, 2002)  and glioblastoma metastasis 
and cell invasiveness (Zagzag, Nomura, et al, 2003).  Unfortunately Hsp90 
inhibition by geldanamycin was also recently shown to activate osteoclast c-
Src signaling and induce prostate carcinoma cells in bone tissues (Yano, 
Tsutsumi, et al, 2008).  This unexpected cancer relapse may be due in part to 
the genetic plasticity and general ability of cancer cells to evade therapeutic 
treatment by the development of drug resistance (La Rosee, Corbin, et al, 
2002). The fact that HSF1 inhibition induces apoptosis among various cancer 
cells without eliciting such a response in non-malignant cells (Figure 2.10) 
(Dai, Whitesell, et al, 2007) emphasizes the importance of identifying and 
isolating novel HSF1 inhibitors to increase the array of therapeutics available 
that are aimed at combinatorial cancer therapy. 
 
2.3.3.  HSF regulates the expression and activity of Hsp83 (Hsp90) 
chaperonin complex 
In this thesis, I have provided previous evidence and further 
demonstrated that HSF1 activity is critical for the proper expression of Hsp83 
during Drosophila animal development.  This HSF1 requirement was first 
suggested by the fact that cytological site 63B which corresponds to the 
Hsp83 locus shows the highest HSF1 occupancy of any site in the Drosophila 
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genome, as well as the fact that Hsp83 is the most highly-expressed protein 
under normal growth conditions, accounting for 1-2% of  the total protein 
content in vivo (Lindquist, 1980; Brugge, Erikson, and Erikson, 1981; 
Oppermann, Levinson, et al, 1981).  As shown here, either iaRNAHSF or HSF1 
RNAi expression in Drosophila causes reduced levels of constitutive Hsp83 
expression.  Hsp83 has a general role in biological processes such as 
spermatogenesis, protein trafficking, signal transduction, cytoskeleton 
organization, and cell survival pathways (Castrillon, Gonczy, et al, 1993; 
Chakraborty, Koldobskiy, et al, 2008; Chen, and Balch, 2006; Lange, Bachi, et 
al, 2000; van der Straten, Rommel, et al, 1997; Yue, Karr, et al, 1999); 
therefore, it is likely that by decreasing Hsp83 mRNA levels via iaRNAHSF 
expression results in abnormal traits that are observed when Hsp83 activity is 
reduced by specifc point mutations (Rutherford, and Lindquist, 1998), albeit at 
much higher frequencies than previously observed among Hsp83 
hemizygotes. Collectively, my data suggest that in Drosophila Hsp83 is an 
HSF1 primary target of activation during normal conditions as well as highly 
responsive to HSF1 inhibition during animal development. 
In human cancer cells, I show that HSF1 inhibition by iaRNAHSF results 
in a moderate reduction in the levels of Hsp90 protein (the Drosophila Hsp83 
homolog).  It is likely that along with the duplication of Hsp90 genes in 
mammals, novel gene regulatory mechanisms have evolved to such a degree 
that Hsp90 partially requires HSF1 function for maintaining its normal levels.  
Nevertheless, because cancer cells require Hsp90 multi-subunit chaperone 
complexes that contain Hsp70 (Powers, Clarke, and Workman, 2008), and the 
fact that aptamer expression results in the downregulation of various Hsp70 
family members, along with reduced levels of Hsp90 client proteins which 
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promote cancer cell survival (Erk1/2) (Figures 2.13 & 2.14), it may be 
concluded that HSF1 inhibition by iaRNAHSF compromises Hsp90 activity in 
vivo.  The significance of this inhibition lies in the fact that Hsp90 has been 
found to bind and regulate the activity of hundreds of cell signaling proteins 
that are often aberrant in cancer (Pratt, and Toft, 2003).  Additionally, 
anthamycin Hsp90 inhibitors affect many of the classical hallmarks of cancers 
that promote cancer cell survival, thus making Hsp90 an attractive therapeutic 
target (Hanahan, and Weinberg, 2000).  Collectively, my data allows me to 
propose a model whereby HSF1 inhibition attenuates cell survival signaling 
pathways by compromising the activity of molecular chaperones in 
transformed cells (Figure 2.16). 
 
2.3.4.  HSF regulates a buffering system that promotes adaptation to 
stress 
The stress response is one of the oldest and most well-conserved 
mechanisms that organisms have evolved to allow cells to survive constantly- 
changing environments. At the core of this stress response is the master 
regulator HSF1, which in many different organisms has been shown to 
regulate the expression of hundreds of genes in response to various forms of 
stress (Birch-Machin, Gao, et al, 2005; Murray, Whitfield, et al, 2004; Trinklein, 
Murray, et al, 2004). Cells have incorporated molecular chaperones as critical 
internal components of the stress response regardless of whether the stress 
originates from internal sources such as oxidation and protein damage that 
often occurs during the process of aging (Soti, and Csermely, 2003), or from 
external sources like nutritional balance, exposure to heavy metals, or extreme 
temperatures (Parsell, and Lindquist, 1993).  In particular, molecular  
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Figure 2.16:  Proposed model for iaRNAHSF mode of action.  HSF1 
inhibition by iaRNAHSF compromises cell survival (MAPK) by compromising the 
activity of the Hsp90/Hsp70 multi-chaperone complex.  Heat shock factor 
(blue), molecular chaperones (red), oncogenic signaling proteins that are 
known to cause cellular transformation (white).  Signaling proteins that are 
attenuated by iaRNAHSF (solid white).  *Arrows indicate direct biochemical or 
genetic interaction, negative signal indicates direct inhibition.  
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chaperones have evolved the ability to properly fold or degrade damaged 
proteins caused by a broad spectrum of stresses.  Given the genetic 
instability, high adaptive capacity and elevated chaperone levels observed in 
nearly every type of cancer cell, it is not surprising that there exist distinct 
differences in the general stress response mechanism between normal and 
malignant cells (Murray, Whitfield, et al, 2004).  Here, I demonstrate that HSF1 
inhibition by iaRNAHSF expression results in the attenuation of highly 
conserved signaling pathways that often promote different classes of tumors in 
humans (Davis, Navolanic, et al, 2003; Jones, Zhang, et al, 2008; McCubrey, 
Steelman, et al, 2006; Navolanic, Steelman, and McCubrey, 2003; Parsons, 
Jones, et al, 2008), possibly by disrupting the functions of members of a larger 
chaperone network that promote cancer cell survival, including Hsp70 and 
Hsp90 family members (Figure 2.14) (Palotai, Szalay, and Csermely, 2008). 
Overall, this study builds upon a previous Hsp83-directed “buffering” 
model (Rutherford, and Lindquist, 1998; Sollars, Lu, et al, 2003), and our data 
support the hypothesis that the master regulator HSF1 regulates the activities 
of a large chaperone network.  In particular, HSF1 inhibition results in an 
altered chaperone-driven buffering system that promotes animal trait variation.  
In mammalian cells, HSF1 regulates a stress-sensitive buffering system that 
allows cells to survive and cope with stress.  Such stress-sensitive buffering is 
central to cancer cell survival since under limiting chaperone conditions many 
oncogenes quickly become degraded.  Given the large diversity of altered 
genetic backgrounds observed among different types of cancers, it will be 
interesting to determine how maintenance of the HSF1-regulated chaperone 
network, or components thereof, contribute to the maintenance of malignant 
phenotypes among various types of tumors. In this work, I provide an in vivo 
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approach that combines an interspecies system aimed at understanding 
HSF1!s function during animal development and its putative role for early drug 
target validation.  Because the HSF1 DNA linker domain is highly conserved 
among eukaryotes, it is likely that iaRNAHSF, or derivatives thereof, will prove 
to be useful in further unraveling HSF1!s role in other model organisms or in 
diseases such as cancer. 
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CHAPTER THREE:  IDENTIFICATION OF THE HSF1-REGULATED 
CHAPERONE NETWORK IN DROSOPHILA MELANOGASTER AND 
HUMAN CELLS 
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3.1. Introduction:   
3.1.1.  Identification of members of the chaperone network regulated by 
HSF1 
In this section, I propose various experiments that attempt to identify 
HSF1 regulated genes in both whole Drosophila melanogaster and various 
human cancer cells in a genome-wide manner.  To identify the members of the 
HSF1 regulated chaperone network, I describe how the inhibition of specific 
HSF1-regulated genes will help unravel HSF1!s general role in the 
maintenance of cell survival in Drosophila and human cancer cells.  Moreover, 
I will describe experiments aimed toward the development of a therapeutic 
model system to test the efficacy of the HSF aptamer in mice.  In all cases, the 
Drosophila system will be used to cross-reference the results isolated from the 
human data.  Lastly, I will describe an ongoing collaboration with Dr. Kazunori 
Hirayoshi!s laboratory using an RNA aptamer that targets the BTB-POZ 
domain of GAGA associated factor and work that I have done to determine its 
function in vivo. 
 
3.1.2.  Elucidating the gene expression network for regulatory and anti-
cancer phenotypes generated upon HSF1 inhibition 
 The fact that iaRNAHSF binds tightly and specifically to HSF1 in both 
Drosophila and mammals allows us to exploit the complementary advantages 
provided by each system.  Using Drosophila as a model system, I plan to 
study the general patterns of gene regulation on HSF1 targets that are well 
conserved between both species.  A significant advantage of using Drosophila 
over other systems is the fact that flies have a single HSF1 gene and any 
results generated in flies should be easier to interpret as opposed to the 
 122 
multiple HSF isoforms in other systems.  Furthermore, performing these 
experiments in Drosophila provides a broad battery of assays not currently 
available in human culture models such as in vivo imaging techniques, and a 
wide collection of mutants that can be used in whole animal studies (Schwartz, 
Werner, and Lis, 2004; Yao, Munson, et al, 2006; Brand, and Perrimon, 1993).  
Importantly, identifying the chaperone network regulated by HSF1 provides a 
great starting framework for determining novel drug targets that are likely to be 
highly relevant in human cancer therapy. 
 I have demonstrated that the expression of iaRNAHSF, which inhibits 
DNA binding of HSF1, causes striking phenotypes in whole Drosophila and 
human cancer cells under normal growth conditions, and has potent anti-
cancerous properties in various cancer cell lines (Chapter 2).  In Drosophila, 
this aptamer evokes a high penetrance of developmental phenotypes that are 
associated with reduced expression of Hsp83/90, and its expression 
suppresses abnormalities induced by gain-of-function mutations in the 
EGFRElp and RafBT98 oncogenes.  In human cancer cell lines, HSF1 inhibition 
by iaRNAHSF expression severely compromises transformation-induced growth 
and promotes apoptosis specifically among cancer cells.  These phenotypes 
can be attributed to the function of the key heat shock proteins Hsp70 and 
Hsp83/90 and their role in regulating the apoptotic and cell survival signaling 
pathways (Chaper 1).  However, to further understand the full gamut of 
changes in gene expression caused by inhibiting HSF1, I propose to inhibit 
HSF1 with iaRNAHSF and measure the immediate changes in gene expression 
using the Drosophila and mammalian cancer cell culture model systems as 
discussed below. 
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3.2.  Surveying the effects of the HSF aptamer on global gene regulation 
in Drosophila 
 To test the effects of iaRNAHSF expression in Drosophila S2 cells, I 
have cloned the aptamer gene under the copper-inducible promoter, since this 
level of aptamer over-expression will allow us to obtain global patterns of HSF 
inhibition at specific time points post aptamer induction.  Transient transfection 
experiments indicate that the addition of copper to S2 cells that contain 
aptamer genes results in high-level iaRNAHSF expression within the first few 
hours following treatment (Figure 3.1).  Stable cell lines carrying these copper-
inducible aptamer genes show that Drosophila S2 cells can effectively show a 
copper response in a dosage-dependent manner (Figure 3.2A) and thus 
induce aptamer RNAs to high cellular concentrations (Figure 3.2B).  At these 
high levels of aptamer expression, iaRNAHSF inhibits HSF1 trans-activation of 
the Hsp70 and Hsp83 loci under both non-inducing and heat shock conditions 
relative to the Rev mock RNA-expressing control (Figure 3.2C).  Moreover, 
iaRNAHSF expression inhibits HSF1 DNA binding activity as observed at the 
Hsp70 loci under non-inducing conditions relative to matched control cells 
(Figure 3.2D).  In these experiments, the relative levels of HSF1 on the Hsp70 
promoter are decreased upon iaRNAHSF expression whenever cells are treated 
with copper sulfate.  Collectively, my results indicate that iaRNAHSF expression 
demonstrates potent HSF1 inhibitory activity in Drosophila S2 cells. 
To identify genes that are regulated by HSF1, I plan to compare the 
various patterns of gene expression following the induction of iaRNAHSF  
versus a control RNA (Rev) and against cells that have been depleted of HSF 
by RNAi.  I plan to examine this using our newly-developed GRO-seq assay  
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Figure 3.1:  Cloning and transient iaRNAHSF expression in Drosophila S2 
cells.  A).  Schematic representation of aptamer polymeric templates cloned 
downstream the copper inducible (methalothienin MtnB) promoter into the 
pDEST48 Gateway destination vector (Invitrogen).  Here, each aptamer gene 
(205bp) is cloned in a head to tail manner and flanked by a self cleaving 
hammer-head ribozyme (hammer) to ensure release of the functional unit 
following a transcription cycle.  B). Determination of iaRNAHSF levels in 
transiently transfected Drosophil a S2 cells mock treated or treated with 5mM 
CuSO4 at specific time points shows that the aptamer genes are responsive to 
copper sulfate addition (iaRNA levels were quantified using qPCR, normalized 
to Rp49, n=3). 
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Figure 3.2:  iaRNAHSF expression inhibits HSF1 activity in Drosophila S2  
cells (A).  Addition of various concentrations of CuSO4 induces the 
endogenous copper responsive gene (MntB) to various levels in two different 
iaRNAHSF stable Drosophila S2 cell lines (white=aptamer polymer of 2; and 
blue bars= aptamer polymer of 8 repeating units) (% total RNA values 
normalized to 18S rRNA, n=3).  B).  Addition of 2.5mM CuSO4 for 38 hrs 
induces high level of HSF aptamer in vivo (blue) in stable cell lines harboring 
iaRNAHSF polymeric templates downstream the copper inducible promoter 
(MtnA) (total RNA is normalized to 18S rRNA; contaminating DNA is plotted in 
gray; n=3).  C). iaRNAHSF expression inhibits HSF1 trans-activation activity 
under non-heat shock (NHS) and heat shock (HS) conditions in vivo.  Black 
bars correspond to the mRNA levels in cell lines harboring a control reverse 
aptamer sequence (Rev), while the blue bars correspond to iaRNAHSF 
expressing cell lines (total mRNA values are normalized to Rp49, n=3).  D). 
Induction of iaRNAHSF expression in stable Drosophila S2 cells (blue bars) 
inhibits HSF1 DNA binding activity to Hsp70 loci under NHS conditions 
compared to control cells (light gray= uninduced iaRNAHSF; black= uninduced 
Rev; gray= induced Rev sequence. % ChIP signal corresponds to total 
antibody signal normalized to the no Ab control, n=2). 
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(Core, Waterfall, and Lis, 2008), which examines nuclear run-on products by 
massive parallel sequencing to provide a highly-sensitive mapping of the 
position, amount, and orientation of transcriptionally-engaged RNA 
polymerases across entire genomes.  Because this method examines nascent 
transcription, it is particularly effective in detecting first-order changes in gene 
expression and will allow tracking of the immediate changes in gene regulation 
that accompany expression of the HSF aptamer.  This is superior to standard 
genome-wide expression assays since GRO-Seq it is not affected by the 
steady state "background! RNA levels commonly detected during template 
hybridization in microarray platforms.   
 The genes showing altered levels of expression using both the HSF 
aptamer and RNAi methods relative to control RNA expressing cells will be the 
primary candidates for further investigation.  I do not expect the results of the 
two methods to be necessarily congruent since the RNAi knockdown of HSF 
requires several days of incubation and therefore may produce secondary 
effects. The RNA aptamer method of inhibition should provide a more direct 
means to examine the primary effects of HSF inhibition given that the aptamer 
can be induced within a few minutes. However, the RNAi results that match 
those obtained with the RNA aptamer will further validate those candidates of 
greatest interest. 
 After identifying HSF1 regulated genes in Drosophila, I plan to classify 
these genes by molecular function, if known, using the GO-terms provided on 
the UCSC genome browser, and determine if these genes have any 
mammalian homologs with similar functions in an attempt to understand their 
putative function in transformation.  
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3.3.  Surveying the effects of the HSF aptamer on global gene regulation 
during carcinogenesis in mammalian cells 
 As a first step towards understanding the involvement of HSF1 in 
tumorigenesis, I propose to identify the primary targets that are regulated by 
HSF1 in primary NHEK (normal human epidermal keratinocytes), IMR90 
(primary human lung fibroblast), and HeLa cells, since these lines are from 
epithelial descent (Lazo, 1988), and the results obtained from these cell lines 
might reveal new insights regarding the role of HSF1 during carcinogenic 
transformation.   
To study the effects of regulated iaRNAHSF expression, I have cloned 
and generated HeLa cells that contain iaRNAHSF genes downstream the 
inducible tetracycline promoter (Figure 3.3).  Treatment of HeLa cells with 
doxycycline as a substitute for tetracycline results in the effective induction of 
apoptosis within a few days following doxyclyne treatment relative to control 
cells (Rev) or parental cell lines that are not treated with doxycycline.  
Unfortunately, the stable aptamer cell lines that I generated in these 
experiments cells began to show reduced doubling rates when compared to 
parental or control cell lines, a defect that is presumably due to the leaky 
expression of the tet-on system.  In spite of this difficulty, I discovered that this 
expression system does not induce any toxic effects on its own and can be 
easily adapted for the regulated expression of aptamer genes.  Therefore, in 
order control the aptamer genes more stringently, I have begun to clone the 
aptamer genes downstream the tet-repressor promoter.  I have already 
generated multiple clonal HeLa cell lines that express the tet-repressor protein  
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Figure 3.3:  Induction of iaRNAHSF from a tetracycline promoter induces 
apoptosis in HeLa cells.  Comparison of HeLa cell viability among stable 
cells that harbor both a control (Rev) aptamer sequence or the HSF aptamer 
(iaRNAHSF) gene under the tetracycline inducible promoter as a function of 
time.  Here, stable cells were established by transfecting either the control or 
the  HSF aptamer into the pDest30 Teton inducible vector, and selecting for 
G418 resistant cells (Invitrogen).  After the selection procedure, induction of 
the reporter genes was accomplished by the addition of1ug/ml doxycycline to 
stable TREX-Hela Teton cells.  General cellular viability in these experiments 
was determined at 36 hrs (black) or 120 hrs using trypan blue staining. 
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to be used as acceptor cell lines in tet-off experiments that have been named 
pTRE tight tet-off clones 1-24.  Using the pTRE Tight tet-off cells, I plan to 
introduce and generate cervical carcinoma cells that contain iaRNAHSF genes 
under tetracycline control and determine the changes in gene expression that 
occur during the early phases of HSF1 inhibition relative to control RNA 
expression. This experiment can be expanded to compare the changes in 
gene expression in NHEK, IMR90, and multiple human cancer lines by taking 
advantage of the high transduction efficiency provided by a retroviral delivery 
system (pRev.TRE Clonetech) or adenovirus (AAV) particles containing 
aptamer expressing genes.  Preliminary experiments show that AAV gives 
high transduction efficiency among a variety of human cancer cells (Figure 
3.4).  By comparing the iaRNAHSF effect on HSF1 inhibition in two normal and 
one transformed backgrounds (NHEK & IMR90 vs HeLa), we will be able to 
obtain a snapshot of the changes in gene expression which are dependent on 
HSF1 activity in epithelial cells using the GRO-seq method.  In a similar 
manner to the Drosophila S2 cell studies above, we can complement the 
above experiments and deplete HSF1 using shRNAi as an independent 
source of HSF1 inhibition.  At the same time, we can confirm the expression 
results generated from the GRO-seq assays and choose candidate genes in 
order to analyze the relative levels of HSF1 occupancy, and their expression 
levels among aptamer expressing or control RNA expressing cells. 
 This strategy will likely identify genes whose expression is affected by 
the aptamer and whose function may promote tumor formation, thus identifying 
specific candidates and possible pathways that play a role in the development 
of a tumor phenotype. Thus, this genome-wide approach has great potential to 
reveal the cascade of transcriptional regulatory events that depend on HSF1  
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Figure 3.4:  Comparison of transduction efficiency of a high titer 
AAV.GFP in various human culture cells.  The following cell lines, MCF7-
human breast cancer cell line, MDA-MB-231 human breast cancer cell line, 
HeLa-human cervical carcinoma, and IMR90-human primary lung fibroblast 
were transduced with an AAV virus that expresses a GFP reporter gene.  In 
comparison to the total cellular population (DIC), the MDA-MB-231 and Hela 
cells show the highest transduction efficiency compared to the MCF7 and 
IMR90 cells (see GFP chanel).  *Infection was allowed to proceed for ~3hrs, 
then the virions were washed away and cells were grown for approximately 60 
hours before visualizing cells under the DIC and GFP channels.   
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transcriptional activity. A potential limitation of this approach is that there may 
be lots of changes and only a subset is critical for the phenotype. Given the 
high degree of functional conservation between human and flies, we can 
cross-reference the global profiles of each organism as a method of narrowing 
the subset of genes that help promote the cancer phenotype. 
 Beyond the scope of these proposed experiments, it is tempting to 
consider that each of these conserved HSF1 regulated genes may play an 
important role in the maintenance of tumors.  Therefore, each HSF1-regulated 
gene identified from the proposed genome-wide analyses could become a 
putative drug target, against which we can begin selecting novel aptamers.  
Each of those aptamer candidates could be introduced into various cancer cell 
lines as described in Chapter 3 in an attempt to identify those aptamers that 
produce slow growth, apoptosis, or terminal differentiation among cancer cell 
lines relative to controls to identify genuine modulators of carcinogenesis.  The 
goal is to isolate aptamers with potent and highly specific anti-tumor properties 
and categorize their activity in the context of a broad spectrum of human 
cancers with the long term goal of obtaining a global transcription profile of 
various types of cancers and an assessment of their overall dependency on 
the chaperone network.   
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CHAPTER FOUR: PERSPECTIVES 
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4.1.  Examining effects of aptamers on mammalian tumor formation  
To establish an aptamer based therapeutic model, future experiments 
should focus on understanding whether local instillation of cancer cells that 
contain small-molecule-inducible forms of the aptamer in mice as mentioned in 
chapter 3.  In these experiments, cancer cells containing the small-molecule-
inducible form of the aptamer should be used in xenografts experiments in 
mice and the transformation capacity, and metastatic potential of the cancer 
cells  should be closely evaluated in the absence or prescence of aptamer 
expression.  In these experiments, aptamer expression will be controlled by 
introducing small-activating molecules (i.e. tetracycline or doxycycline) within 
the food, or by direct injection of the small-activating molecules into the 
bloodstream of the mice.   
As an alternative approach toward establishing an aptamer based 
therapeutic model, aptamer expression can be delivered into mature tumors 
using a "gene therapy approach!, where recombinant viruses that contain 
aptamer-expressing genes are injected directly into cancerous tissues/sites in 
mice.  In this approach, the efficacy of the aptamer will be tested by comparing 
the size of the treated tumors at specific time points relative to a paired RNA 
control.  We can expect that those tumours that are sensitive to HSF1 
inhibition will respond well to the aptamer based viral therapy.  However, for 
those types of cancers that are resistant to HSF1 inhibition by the aptamer, it 
will be interesting to determine if these particular types of cancers are more 
suceptible to traditinal forms of cancer therapy such as radioation or 
chemotherapeutic treatment.   
Overall, this analysis should reveal the potential therapeutic value of the 
HSF1 aptamer during the various stages of tumor progression in specific 
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human cancer cells, at the same time, allow us to predict the therapeutic value 
of the aptamer againts a wide collection of pre-existing tumors caused by 
specific mutagens (or deregulated proteins) in a mammalian system in vivo. 
 
4.2  Dissecting the mechanism of aptamer action in Drosophila 
 The powerful Drosophila genetic system allows for a thorough 
investigation of the mode of action of aptamer expression in a non-
transformed genetic background.  In this system, we can explore the changes 
in gene expression induced by HSF1 inhibition by iaRNAHSF in the context 
where specific mutations such as inactivated tumor suppressors or 
hyperactivated oncogenes can be easily and quickly manipulated in a whole 
animal.  By expressing aptamers in such specified genetic backgrounds, we 
will be able to analyze the relationship between HSF1 and specific HSF1-
regulated gene targets that are known to promote oncogenesis in mammals.  
Given that in cancerous cells contain hundreds of genetic mutations and 
aberrations, one advantage of our Drosophila model of tumorigenesis is that 
we will be able to analyze the effects of specific cancer inducing mutations in 
an a "clean! genetic background, thereby allowing us to study the genetic 
interactions between HSF1 and specific cancer causing mutations.  At the 
same time, we will be able to score the hierchy of each of these genetic 
interaction and determine how each contribute to deregulated cell growth 
using our tissue specific tumor models in flies, the eyes and wings as 
mentioned in chapter 2.  
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4.3  Morphological effects of aptamers on specific oncogenic 
backgrounds 
 I have previously demonstrated that aptamers and specific cancer 
mutants can be expressed in specific tissues or developmental stages in 
Drosophila by placing each target under the tight genetic control of the UAS-
Gal4 system (Chapter 2).  In brief, this strategy works for our existing HSF 
aptamer by examining its effects on gain-of-function mutants within the MAPK 
signaling pathway, Raf and EGFR gain-of-function mutants.  As shown in 
Figure 2.9, I have demonstrated that the morphological abnormalities induced 
by the oncogenic mutant protein are effectively suppressed by HSF aptamer 
expression, demonstrating that this strategy provides a convenient and 
quantitative measurement of aptamer function in vivo.  These assays can be 
used with additional aptamers that have putative anti-oncogenic potential.  Not 
only can single oncogene mutations be used in such assays, but given the 
ease and power of Drosophila genetics, one can also introduce multiple 
specific combinations of such mutations to elucidate the relationship of 
signaling nodes and their dependence on the chaperone network.  
 
4.4  Global regulatory changes caused by aptamers on specific 
oncogenic backgrounds 
 In Drosophila, we can explore the global changes in gene expression 
between aptamer-expressing cells either lacking or expressing specific 
oncogenes in order to assess the relationship between a particular oncogene 
and the chaperone network using the GRO-seq protocol.  The large amount of 
expression information from each two-by-two matrix comparing normal and 
cancer-modeled cells with and without aptamer will yield genes that will be 
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divided into classes.  In the first case, we will identify the genes most affected 
by inhibiting the entire network of proteins whose expression is dependent on 
HSF1 activity by expressing iaRNAHSF.  With the availability of our newly-
generated aptamers to individual HSF1-regulated proteins, many of which we 
expect will be chaperone network members (Chapter 2), we can identify how 
each member of the network contributes to the maintenance of the entire 
network by classifying the subsets of genes affected upon inhibition.  The 
effects of specific oncogenic backgrounds on these patterns of gene 
expression in cells that express aptamers to HSF1 (or specific chaperones) 
will identify those genes that are either affected or indifferent to this 
”chaperone therapy”.  This information will sharpen current strategies for the 
treatment of various classes of tumors since this analysis will identify new 
classes of gene that contribute to the deregulated cell growth associated with 
specifc cancers. For example, we envision that an aptamer to HSF1 will affect 
a large number of genes, while an aptamer to a specific chaperone will affect 
only a small subset.  If both have comparable abilities to reverse the effects of 
a specific oncogene, then clearly the aptamer targeting a specific chaperone is 
the preferred reagent as a therapeutic lead.  At the same time, but beyond the 
scope of this analysis, those genes that differ between oncogenic and normal 
cells but are not changed upon aptamer expression can be classified as 
putative novel drug targets worthy of aptamer selection specific to that 
particular abnormal genetic background or cancerous condition.  The number 
of two-by-two matrices generated would depend on the number of aptamers 
with anti-oncogenic activity identified and the number of oncogenic 
backgrounds available in the Drosophila community.  For starters, we will also 
focus on a few of the best-characterized oncogene and tumor suppressor 
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mutants in Drosophila, including members of the receptor tyrosine kinase 
family such as EGFR, members of the Raf mitogen-activated signaling 
pathway, and classic tumor suppressors such as p53 and Rb.  Lastly, a similar 
analysis will be performed in non-transformed human cells by introducing 
specific cancer-causing mutations to compare expression profiles with and 
without the introduction of specific aptamer RNAs.  
In conclusion, the proposed battery of assays will allow for the 
assessment of the modes of action of a particular aptamer in a single mutant 
background or in backgrounds of specific combinations of mutants. The 
interplay of both the mammalian and Drosophila systems provides an efficient 
and cost-effective means of assessing the anti-cancer properties and mode of 
action of RNA aptamers, and their utility as therapeutic inhibitors in vivo. 
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CHAPTER FIVE:  MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This chapter includes the techniques and reagents used in my experiments.   
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Oligonucleotides and other reagents 
A single iaRNAHSF unit was constructed in two parts by extending 
50pmoles of each of the following primer sets (I & II; III & IV) in 100ul using a 
single round PCR reaction: 
 
I).5!CCGCTCGAGTGACGTTGGCATCGCGATACAAAATTAAGTTGAACGCG
AGTTCTTCGGAAT, 
II).5!GGCCGGAATTCAAGGAGTATGACGAAGGCAGTTGAATTCCGAAGAAC
TCGCGTTCAACTT 
 
III).5!GGCCGGAATTCAACTGCCTTCGGGCATCGCGATACAAAATTAAGTTG
AACGCGAGTTCTTGGAGGCTCGACGTCT, 
IV).5!CGCGTCGACGTTTCGTCCTCACGGACTCATCAGTAGCGAAACCACA
TCGCTAGACGTCGAGCCTCCAAGAACTCG.   
 
After extension, the resulting products were visualized by EtBr staining and 
extracted from an 8% native polyacrylamide matrix.  Then, each template was 
digested with EcoRI (Invitrogen), and ligated together resulting in a product 
that contains two individual aptamer genes (Apt-HSF1) and a self-cleaving 
hammerhead ribozyme (iaRNAHSF).  The iaRNAHSF product was cloned into 
pstBlue-blunt cloning vector pstBlue.iaRNAHSFX1 (Novagen).   
 
Construction of synthetic genes 
Repetitive head-to-tail iaRNAHSF genes were created by sub-cloning 
iaRNAHSFX1 into a Gateway donor vector (pDONR221.iaRNAHSFX1) by 
amplifying the iaRNAHSFX1 sequence from pstBlue.iaRNAHSFX1 using primers 
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containing the AttB1F and AttB2R Gateway cloning sequences (Invitrogen): 5! 
AAGTTTGTACAAAAAAGCAGGCTTCGGATCCAGAATTCGTGATC and 5! 
GGGGACCACTTTGTACAAGAAAGCTGGGTTAGCCTAGGTCGACG.  
Because each iaRNAHSF unit is flanked by the complementary asymmetric 
XhoI and SalI restriction sites at the 5! and 3! ends, respectively, we can use 
the general Gateway cloning strategy as a way to select for correctly ligated 
tandem iaRNAHSF repeats.  In this method, a single iaRNAHSFX1 unit is first 
amplified from pDONR221.iaRNAHSFX1 via PCR and the resulting amplicon is 
cut with either SalI or XhoI before the cut products are combined and ligated 
together.  Using this scheme, only those products that are in proper head-to-
tail orientation contain the required Gateway AttB sites in the 5! and 3! ends 
(AttB1F.iaRNAHSFX2.AttB2R) needed for creation of a- Gateway compatible 
Drosophila transformation expression vector, pUAS.iaRNAHSFX2.  Using the 
polymer of 2 as template and repeating the dimerization strategy creates a 
polymer of 4, p{UAS.iaRNAHSFX4, w+}.   Overall, geometric progression of 
polymeric length is achieved in each subsequent round of dimerization.   
 
Drosophila strains  
Parental iaRNAHSF animals were created by injecting Drosophilaw1118 
embryos with p{UAS.iaRNAHSFX8, w+} and p{UAS.iaRNAHSFX16, w+} 
transformation vectors and screening the progeny of F1 females for animals 
that contain the mini-white gene when crossed to a doubled balanced CSX fly 
line: CyO(2); TM6(3); Xasta(2,3).  Sites of p-element insertions were 
determined genetically by continuous backcrossing to the CSX stock, resulting 
in homozygous fly lines that contain aptamer genes in various chromosomes: 
1. UAS.iaRNAHSFX8(I) 2. UAS.iaRNAHSFX16(I) 3. UAS.iaRNAHSFX8,16(I) 4. 
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UAS.iaRNAHSFX8(II) 5. UAS.iaRNAHSFX16(II) 6. UAS.iaRNAHSFX8,16(II) 7. 
UAS.iaRNAHSFX16(III).  To express iaRNAHSF, we crossed homozygoous 
UAS.iaRNAHSF stock animals with various Gal4 sources purchased from the 
Drosophila Stock Center (Bloomington, IN): 6983 (Salivary Gland Gal4), 5138 
(Ubiquitous tubulin Gal4).  Systemic iaRNAHSF expressing strains were created 
by isolating F1 females from aptamer parental containing aptamer genes in the 
second chromosome (UAS.iaRNAHSF8 & UAS.iaRNAHSF8,16) mated to 5138 
animals.  Heterozygous F1 males were then mated to CSX females, and the 
resulting F2 animals that contained both aptamer genes and Gal4 protein 
(UAS.iaRNAHSF/CyO; Tub.Gal4/Sb) were isolated and isogenized to create 
true breeding aptamer expressing lines.  Other Bloomington stocks used in 
this study include 5693 (Hsp83e6D antimorphic mutant) and 5743 (Duplication 
61F7-F8; 64B10-12).  The pUAS.eGFP strain was given as a gift from Dr. 
Antonio Garcia-Bellido!s laboratory, while strains expressing the gain of 
functions EGFrElp and RafBT98 mutants were also gifts kindly provided by Dr. 
Marc Therrien.   
 
In vitro binding assays 
Internally labeled 32P-UTP iaRNAHSF was transcribed from a iaRNAHSFX1 
PCR template containing a 5!-T7 promoter using a Maxi-script Kit (Ambion).  
Electrophoretic motility shift assays (EMSA) were performed by addition of 
increasing molar amounts of purified GST-HSF protein to limiting amounts of 
32P-iaRNAHSF (<1nM) using the following binding conditions: 25mM Tris HCl, 
75mM KOAc, 0.5Mm MgCl2, 10% glycerol, pH=7.4, and allowing complexes to 
form for 0.5 hrs at 25°C.  RNA/protein complexes were separated in 6% native 
agarose gel (3mM Tris HCl, 200mM glycine, 0.5mM MgCl2).  Competition 
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experiments were performed by incubating increasing molar amounts of cold 
iaRNAHSF together with labeled Hsp83 or Hsp70 promoter DNAs followed by 
the addition of 50nM purified HSF-GST for 30 minutes at room temperature.  
The resulting complexes were then separated on 2% agarose gels (0.5X TAE, 
0.5mM MgCl2) or passed over nitrocellulose filters used for quantification in 
filter-binding assays.  Promoter DNA sequences were amplified from 
Drosophila genomic DNA using the following primer sequences: Hsp83-449F: 
5!-ACTTGACTGGGCTTGTAGCAGGTT,Hsp83+114R:5! 
TTCTGGATGCCAGGGATGCAACTT,Hsp70–200F:5!-
TGCCAGAAAGAAAACTCGAGAAA,Hsp70+64R:5!-
CTGCGCTTGTTTGTTTGCTTAGCT  
 
RNA quantification 
Total RNA was extracted from whole animals using Trizol reagent 
(Invitrogen).  Quantification of the relative transcript levels was determined by 
oligodT20 reverse transcription, followed by real time PCR analysis (RT-qPCR) 
using the following primer sets:  
Rp49+141F: 5!-CCCAAGGGTATCGACAACAGA,  
Rp49+204R: 5!-CGATGTTGGGCATCAGATACTG,  
18S +417F: 5!-TGACGAAAAATAACAATACAGGACTCA,  
18S +569R: 5!-CAGACTTGCCCTCCAATTGG,  
iaRNAHSF F: 5!-TGGTTTCGCTACTGATGAGTCCGT,  
iaRNAHSF R: 5!-GCAGTTGAATTCCGAAGAACTCGC,  
Hsp70Ab+2155F:5!- GGTCGACTAAGGCCAAAGAGTCTA,  
Hsp70Ab +2266R:5!- TCGATCGAAACATTCTTATCAGTCTCA,  
 
 147 
Hsp83 + 3628F: 5!-GCGACCAGTCGAAACAAACAACCA,  
Hsp83 + 3732F: 5!-AACTCGGCCGTAGTAAACTCAG,  
Hsp26+580F: 5!-CAAGGTTCCCGATGGCTACA,  
Hsp26+667R:5!-CTGCGGCTTGGGAATACTGA 
 
Statistical analysis 
All statistical analyses were calculated using student!s t-test. 
 
Immunofluorescent assays of polytene chromosomes 
Salivary glands were dissected from third stage instar larvae in 0.5X 
Grace!s medium.  Chromosomes were spread, fixed onto slides and 
immunostained using antibodies targeting HSF, GAGA Factor (GAF) as 
described previously in Shwartz et al (Schwartz, Werner, and Lis, 2004).   
 
Morphological studies 
Aptamer-expressing animals were scored for phenotypic abnormalities 
using a dissecting microscope.  Pictures were taken using an 8.0Mb Nikon 
digital camera.  Quantification of morphological abnormalities was calculated 
by quantifying abnormal size or area using the ImageJ software (NIH). 
 
Tissue Culture  
iaRNAHSFX8 was subcloned into Gateway pDEST48 (Invitrogen) and 
stable Drosophila S2 cells were stably selected by maintaining cells in 6 ug/ml 
Blasticidin reagent.  iaRNAHSF was induced using 0.5mM CuSO4.   
Mammalian IMR90, and HeLa cells were grown in E-MEM low glucose 
medium (ATCC) supplemented with 10% FBS, 1X Pen/Strep in 5% CO2.  
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293T cells were grown in DMEM high glucose medium (ATCC) supplemented 
with 10% FBS, 1X Pen/Strep in 5% CO2.  MDA-MB-231 cells were grown in 
RPMI medium (ATCC) supplemented with 10% FBS, 1X Pen/Strep in 5% CO2.  
BE-(2)-M17 cells were grown in 1:1 EMEM low glucose medium (ATCC) + F12 
medium (ATCC) supplemented with 10% FBS, 1X Pen/Strep in 5% CO2.  
Upon confluency, cells were trypsinized and passed into fresh medium 
according to ATCC instructions.  
For all constitutive level expression experiments, iaRNAHSFX8 was 
subcloned into Gateway pDEST51 (Invitrogen) and semi-stable cells were 
maintaining cells in 0.5-6ug/ml Blasticidin reagent depending on the cell type.  
For generation of Tet-on stable cells, iaRNAHSFX8 was subcloned into Gateway 
pDEST30 (Invitrogen) and stable cells were generated by transfecting 
iaRNAHSF into HeLa-Trex (Invitrogen) and maintaining the cells in 100ng/ml 
G418 until drug resistant cells appeared.  iaRNAHSF was delivered into 
mammalian cells using Lipofectamine (Invitrogen) or Lipofectine (Quiagen) 
transfection reagents according to the manufacturer!s instructions. 
 
Apoptotic Assays: 
Apoptosis was observed by quantifying the number of HeLa cells 
containing fragmented nuclei as visualized by DAPI staining under the 
microscope.  In these experiments, parental, iaRNAHSF or Rev RNA control 
cells were transfected and apoptosis was observed for after 96 hrs of aptamer 
expression.  In these experiments, non-transfected iaRNAHSF or RNA control  
cells were subsequently discarded from the population by culturing the cells in 
6 µg/ml blasticidin and washing the cells 24 hrs after transfection.  Only the 
blasticidin-resistant cells were used throughout subsequent assays. 
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Transformation Assays: 
Transformation was determined by the ability of cells to grow on soft 
agar.  In these experiments, 6x103 semi-stable cells were plated on 6-well 
dishes in appropriate medium supplemented with 3% agarose (Type VII, 
Sigma A4018) over a warm layer of pre-solified medium containing 6% 
agarose (Type VII, Sigma A4018).  On day 7 and additional layer of medium 
containing 3% agarose was added to each of the wells.  Colonies were 
analyzed under the light microscope on day 14. 
 
Western Blots: 
Western blots were performed according to conventional protocols.  
PVDF membranes were blocked  using 5% BSA and membranes were 
incubated primary antibodies overnight at 4°C.   
Primary Antibodies:  G6PDH was purchased from Sigma (A9521).  
PARP DBD was a kind gift from Lee Kraus! group.  All other antibodies were 
purchased from Cell Signaling Inc.:  EGFR~p (No. 2234), Erk1/2~p (No.9146), 
total Erk1/2 (No. 9102).  Hsp40 (No.4868), Hsp60 (No. 4870), Hsp70 (No. 
4872), Hsp90 (No. 4875), HSF1 (No. 4356), Calnexin (No. 2433), PDI (No. 
2446), Bip (No. 3177).  
Secondary antibodies were used according to proper immunoreactivity. 
 
RNAi: 
Templates for generating dsRNA were generated by amplifying 
genomic DNA using the following primer sets containing a T7 promoter and 
dsRNA was generated by in vitro transcription.  RNA was DNAse I treated, 
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phenol:chloroform extracted, and the RNA was heated and cooled, producing 
dsRNA.    
T7Hsp83+378F:  
5!-TAATACGACTCACTATAGGGTTCCATGATCGGTCAGTTCGGTGT, 
T7Hsp83-1048R: 
5!-TAATACGACTCACTATAGGGCGTACAGCTTGATGTTGTTGCGCT 
T7HSF F: 
5!GAATTAATACGACTCACTATAGGGAGAGCCTTCCAGGAGAATGCA, 
T7HSFR: 
5!GAATTAATACGACTCACTATAGGGAGAGCTCGTGGATAACCGGTC 
RNAi Treatment 
~1x106 Drosophila S2 cells were incubated with 10 µg dsRNA targeting 
HSF and Hsp83 for 5 days using genes containing T7 promoter which targeted 
each sequence amplified from Drosophila genomic DNA. 
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APPENDIX 
Dissecting the role of GAGA Associated Factor using RNA Aptamers 
targeting the BTB-POZ domain 
As part of an ongoing collaboration with Dr. Kazunori Hirayoshi!s group 
(Kyoto University, Japan), I engineered a divalent RNA aptamer (iaRNAGAF1-14) 
comprised of two previously-selected aptamers that target the GAP BTB-POZ 
domain (Figure A.1).  Biochemical assays from Dr. Hirayoshi!s group showed 
that each of these aptamers bind avidly to GAF with an approximate 
dissociation constant of 30nM, and can inhibit Hsp70 expression in vitro 
transcription assays.  Using their system, Dr. Hirayoshi!s group showed that 
iaRNAGAF1-14 has an approximate Kd of 5nM (Figure A.2A).  In a similar 
manner as the HSF1 aptamer described in Chapter 2, I made tandem head-to-
tail polymeric constructs of iaRNAGAF1-14 of 8 repeating units, each flanked by a 
self-cleaving hammerhead ribozyme, and cloned this long template 
downstream of either the inducible MntB promoter or the Gal4 (UAS) inducible 
promoter for generating stable Drosophila S2 lines or expression of the 
aptamer in whole Drosophila, respectively.   
 Expression of the aptamer via addition of 2.5mM copper sulfate to cells 
effectively reduces induction of Hsp70 following a heat stress relative to 
control expressing cells (Figure A.2B).  In whole Drosophila, I induced aptamer 
expression in flies (F1) by mating animals that constitutively and ubiquitously 
express Gal4 protein with homozygous aptamer (non-expressing) animals 
(F0).  As heterozygotes, iaRNA
HAF1-14 expressing animals do not display any 
gross abnormalities, yet by increasing the aptamer dosage by generating true-
breeding fly lines, I see various abnormal phenotypes that phenocopy known  
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Figure A.1:  Design of an RNA aptamer targeting GAGA factor (GAF), 
iaRNAGAF1-14. (A).  M-fold prediction of iaRNAGAF1-14 secondary structure and 
direct sequence.  (Red Letters indicate the aptamer sequence; Yellow Letters 
indicate the hammer head ribzyme). 
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Figure A.2:  iaRNAGAF1-14 binds to GAF in vitro and in vivo.  
A).  Gel shift analysis shows that radiolabelled divalent GAF construct 
(iaRNAGAF1-14) binds more avidily to increasing concentrations of purified GAF 
protein than the single aptamer isoforms, Apt1 & Apt14, and displays an 
apparent dissociation constant of Kd~5nM. B).  Expression of iaRNAGAF1-14 
from stable Drosophila S2 cells inhibits the heat shock induction of Hsp70 
mRNA relative to control RNA expressing cells (WT).  *In these experiments, 
cells harboring the aptamer genes under the copper inducible promoter were 
treated with 2.5mM copper sulfate for 36 hours before treating them with 37C 
for 20 min and isolating RNA (fold mRNA is normalized to the internal control 
Rp49 gene, n=3).  C).  High level constitutive expression of iaRNAGAF1-14 (right) 
in whole flies induces an abnormal abdomen segment phenotype (arrow) in 
whole animals relative to parental non-iaRNAGAF1-14 expressing animals 
(middle), or compared to Gal4 expressing animals (left).  Here, the iaRNAGAF1-
14  expressing animals (right) are homozygous within the second chromosome 
and contain a polymer of 8 aptamer genes and also express Gal4 protein 
under the regulation of the tubulin promoter on the third chromosome.  (Left: 
Tubulin Gal4 parent;  Middle:  WT iaRNAGAF1-14  parent;  Right: Tubulin Gal4  + 
iaRNAGAF1-14).  
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GAF point mutants (Bejarano, and Busturia, 2004).  In this regard, , iaRNAHAF1-
14 expression results in Drosophila animals with abnormal pupal shapes, pupal 
lethality, or transformed abdominal segments (Figure A.2C), although many of 
these phenotype occur at low frequency (<5%).    
 Besides the abdominal segment phenotype observed in iaRNAGAF1-14 
expressing flies, I find that true breeding iaRNAGAF1-14  animals display 
abnormal longitudinal veins where the primary vein lacks many of the marginal 
hairs.  Moreover, I find that such true breeding stocks are hard to maintain 
because these vials have low fecundity.  In an attempt to address the 
specificity of the GAF aptamer and suppress these aptamer induced 
phenotypes, I tried over-expressing GAF-GFP protein, however, I found that 
GAF-GFP over-expression results in animal lethality by itself, and this 
phenotype is not suppressed by the aptamer (data not shown).  These results 
suggest that the aptamer is not present at sufficient levels to effectively inhibit 
the aberrant functions of GAF-GFP over-expression, or alternatively, that 
iaRNAGAF1-14  has non-specific properties and binds to other proteins in vivo.  In 
this regard, I compared the relative homology of the GAF BTB-POZ domain 
against all other annotated protein domains within the Drosophila genome, 
and found that many Drosophila proteins contain a BTB-POZ domain, 
including the longitudinal lacking protein (p val=5x10-22) and fruitless (p-
val=2x10-15) gene.  It is likely that iaRNAGAF1-14  binds to and inhibits these 
proteins resulting in not only the abnormal wing margin defect, the low 
fecundity rates, and also the abnormal mating behaiviours observed among 
iaRNAGAF1-14 expressing male flies.  In this last scenario, iaRNAGAF1-14  males 
display a similar defect that is also present among fruitless mutants where the 
males tend to court and attempt to mate with other male flies.  
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Having demonstrated that iaRNAGAF1-14  inhibits GAF trans-activation 
function in vitro (Kazunori et al., in preparation), I measured the levels of 
Hsp26, Hsp70 and Hsp83 genes under both non-inducing and heat shock 
conditions in constitutively aptamer expressing animals but found no 
significant change in the levels of heat shock gene expression  among 
iaRNAGAF1-14  expressing or control animals in either condition (data not 
shown).  However, recent findings suggest that stable-copper inducible 
iaRNAGAF1-14 Drosophila S2 cell lines have decreased Hsp70 mRNA 
transcripts relative to control RNA expressing cells.  It is likely that these 
differences are due to higher levels of aptamer RNA in culture cells when 
expressed from the copper inducible promoter as compared to the constitutive 
level expression in Drosophila animals mentioned previously.  Future 
experiments should focus on the role of GAF in maintaining the promoter in an 
open conformation, its role in promoting HSF1 binding to heat shock elements 
at Hsp70, regulating chromatin architecture, and the establishment of a 
transcriptionally-engaged yet paused polymerase using the copper inducible 
iaRNAGAF1-14 Drosophila S2 cells.   
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